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ABSTRACT
At the present time, there are many hurdles to overcome in order to create a long-lasting
and engineered tissue for tissue transplant in patients. The challenges include the
isolation and expansion of appropriate cells, the arrangement of assorted cells into correct
spatial organization, and the development of proper growth conditions. Furthermore, the
creation of a three dimensional engineered tissue is limited by the fact that tissue
assemblies greater than 100-200 micrometers, the limit of oxygen diffusion, require a
perfused vascular bed to supply nutrients and to remove waste products and metabolic
intermediates. To overcome this limitation, this thesis aims to pre-seed a tissue
engineered construct with vascular cells (both endothelial and perivascular cells), so the
vascular cells could readily form functional vessels in situ. Previous work in the
laboratory had successfully demonstrated the formation of functional microvascular
network by co-implantation of human umbilical cord vein endothelial cells (HUVECs)
and 10 T 1/2 cells, a line of mouse embryonic fibroblasts.
To translate this concept to the clinic, we need to utilize cells that can be secured and
used in clinic. To this end, we systematically replace each individual vascular cell type
with a readily available source of cells. First, we investigated human embryonic stem
cells (hESCs) derived endothelial cells. We demonstrated that when hESCs derived
endothelial cells were implanted into SCID mice, they formed blood vessels that
integrated into the host circulatory system and served as blood conduits. Second, we
compared the formation and function of engineered blood vessels generated from
circulating endothelial progenitor cells (EPCs) derived from either adult peripheral blood
or umbilical cord blood. We found that adult peripheral blood EPCs formed blood vessels
that were unstable and regressed within three weeks. In contrast, umbilical cord blood
EPCs formed normal-functioning blood vessels that lasted for more than four months.
These vessels exhibited normal blood flow, perm-selectivity to macromolecules and
induction of leukocyte-endothelial interactions in response to cytokine activation similar
to normal vessels. Third, we evaluated human bone marrow-derived mesenchymal stem
cells (hMSCs) as a source of vascular progenitor cells. hMSCs expressed a panel of
smooth muscle markers in vitro and cell-cell contact between endothelial cells and
hMSCs up-regulated the transcription of smooth muscle markers. hMSCs efficiently
stabilized nascent blood vessels in vivo by functioning as perivascular precursor cells.
The engineered blood vessels derived from HUVECs and hMSCs remained stable and
functional for more than 130 days in vivo. On the other hand, we could not detect
differentiation of hMSCs to endothelial cell in vitro and hMSCs by themselves could not
form conduit for blood flow in vivo. Similar to normal perivascular cells, hMSCs-derived
perivascular cells contracted in response to endothelin-1 in vivo. Thus, our work
demonstrates the potential to generate a patent and functional microvascular network by
pre-seeding vascular cells in a tissue-engineered construct. It serves as a platform for the
addition of parenchymal cells to create a functional and vascularized engineered tissue.
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Chapter 1: Background and Specific Aims
Introduction
Mechanistic studies of the angiogenesis and vasculogenesis in mouse models have
provided tremendous biological insight. However, mouse models may not faithfully
reproduce human physiology. Alternatively, experiments can be performed in vitro with
human endothelial cells, but there is a drawback in that the initiation and maintenance of
blood flow cannot be easily mimicked in vitro. Therefore, there is a real need to develop
a better in vivo model of angiogenesis and vasculogenesis with human vascular cells.
Besides the gain in basic biological understanding, the ability to manipulate the growth of
new blood vessels with human vascular cells will directly impact regenerative medicine.
It is clear that angiogenesis, the growth of new vessels from pre-existing blood vessels,
plays a critical role in tissue repair and regeneration. Defect in angiogenesis is observed
in patients with ischemic peripheral disease and delayed wound healing. In such cases,
direct injection of vascular cells (both endothelial cells and perivascular cells) may offer
an alternative approach to enhance the revascularization of an ischemic tissue. Besides
this, the ability to create a patent microvascular network will significantly impact the
engineering of functional tissue. Tissue engineering is a discipline that "applies the
principles of biology and engineering to the development of functional substitutes for
damaged tissue."[1] An increasing number of Americans today suffers from tissue loss or
end-stage organ failure (ie. myocardial infarction and renal failure) and often times, the
only viable therapeutic option is surgical repair or replacement of the defective tissues or
organs. Approximately 8 million of such surgical procedures are performed annually[2].
Although tissue and organ transplants can offer dramatic improvement in quality of life
for patients, they have severe limitations. First, the demand for organs far outstrips
supply. In 2005, there were 89,884 patients on the transplantation waitlist, but only
27,527 patients were recipients of transplanted organs and 7,193 patients died while on
the waitlist[3]. Furthermore, allograft transplants entail a life-long regimen of immuno-
suppression that often results in frequent infections and elevated risk for certain
cancers[4]. One possible solution to the severe shortage of tissues and organs for
transplant is to engineer such tissue artificially or to regenerate the diseased tissue in situ.
At the present time, there are many hurdles to overcome in order to create a long-lasting
and patent engineered tissue for tissue transplant. The challenges include the isolation
and expansion of appropriate cells, the arrangement of assorted cells into correct spatial
organization, and the development of proper growth conditions. Furthermore, the
creation of a three dimensional engineered tissue is limited by the fact that tissue
assemblies greater than 100-200 micrometers, the limit of oxygen diffusion, require a
perfused vascular bed to supply nutrients and to remove waste products and metabolic
intermediates[5]. To overcome this limitation, a tissue engineered construct could be pre-
seeded with both parenchymal cells and vascular cells (both endothelial and perivascular
cells), so the vascular cells could readily form functional vessels in situ. Previous work in
the laboratory had successfully demonstrated the formation of functional microvascular
network by co-implantation of human umbilical cord vein endothelial cells (HUVECs)
and 10T1/2 cells, a line of mouse embryonic fibroblasts. The goal of this thesis is to
systematically replace HUVECs and 10T1/2 cells with clinically applicable sources of
vascular cells and demonstrate their effectiveness in creating functional microvessels in
vivo. This thesis aims to derive endothelial and smooth muscle precursor cells from
human embryonic stem cells (Chapter 2) and human progenitor cells from peripheral
blood (Chapter 3), umbilical cord blood (Chapter 3) and bone marrow (Chapter 4).
In addition, previous data demonstrated that endothelial cells, when implanted alone, do
not form stable and long-lasting vessels. This may be due to a deficiency in the
recruitment of host perivascular cells during the critical early time period. This thesis
aims to enhance the recruitment of host perivascular cells by genetically engineering the
endothelial cells to secrete PDGF-BB, a chemotatic factor for perivascular cells (Chapter
5).
Specific Aims
Overall Hypothesis: Heterotypic interaction between endothelial and smooth muscle
precursor cells directs their differentiation and provides bi-directional survival
signals to form stable and long-lasting microvascular network in vivo.
Specific Aim 1: Differentiate endothelial precursor cells from human embryonic stem
cells and demonstrate their in vivo vasculogenic capacity.
Human embryonic stem cells (hESCs) hold tremendous clinical potential due to their
ability to differentiate into all the different cell types in a body. However, it is
challenging to obtain a large number of lineage specific cells. This study intends to
develop a simple differentiation procedure to derive a relatively pure population of
endothelial precursor cells from human embryonic stem cells. Furthermore, the
endothelial precursor cells will be evaluated for their capacity to form functional blood
vessels in vivo.
Specific Aim la: Differentiate endothelial precursor cells from human embryonic stem
cells.
Human embryonic stem cells will be differentiated either three dimensionally in
embryoid bodies or two-dimensionally in monolayer. The efficiency of embryonic stem
cell differentiation will be determined by FACS analysis of CD31+CD34+ cells at a
different timepoint. Once the optimal timepoint has been identified, the endothelial
precursor cells will be isolated by magnetic bead sorting for CD34+ cells. The CD34+
cells will be cultured in endothelial growth medium to promote the proliferation of
endothelial cells. The endothelial phenotype of the hESC-derived cells will be evaluated
by immunostaining for endothelial markers including CD31, VE-Cadherin, and von
Willebrand Factor, and uptaking of Dil-labeld acetylated low-density lipoprotein.
Specific Aim ib: Determine the in vivo vessel forming capacity of human embryonic stem
cell derived endothelial precursor cells.
The hESC derived endothelial cells will be co-implanted with 10T1/2 cells in a collagen
gel in a SCID mouse installed with a cranial window. The enhanced green fluorescent
protein (EGFP) labeled endothelial cells will be imaged with intravital multiphoton laser
scanning microscopy. The endothelial cells will be monitored periodically to determine
whether they have integrated into the host circulation.
Specific Aim 2: Determine the in vivo vasculogenic capacity of human endothelial
progenitor cells.
In order to apply our technique with a source of vascular cells that is closer to clinical
use, here we isolated and characterized the phenotypes of endothelial progenitor cells
derived from peripheral blood and umbilical cord blood. The endothelial progenitor cells
were examined for their expression of endothelial markers. The two sources of
endothelial progenitor cells were then directly compared for their in vivo vasculogenic
potential in forming stable microvascular network.
Specific Aim 2a: Isolate and culture endothelial progenitor cells from human peripheral
blood and umbilical cord blood
Mononuclear blood cells will be isolated from human peripheral blood and umbilical
cord blood by density gradient centrifugation over Ficoll solution. The mononuclear
blood cells will then be cultured with endothelial growth medium on a culture dish coated
with fibronectin. The formation of endothelial outgrowth colonies will be assessed and
the endothelial cell colonies will be subcultured. Expression of endothelial markers will
be evaluated by both immunostaining and fluorescence activated cell-sorting (FACS)
analysis.
Specific Aim 2b: Evaluate the ability of EPC-derived endothelial cells to form functional
vasculature in vivo.
The EPC derived endothelial cells will be transduced with retrovirus to express enhanced
green fluorescent protein (EGFP). The labeled endothelial cells will be incorporated with
or without 10T1/2 cells, a line of murine embryonic fibroblasts, in a Type I
collagen/fibronectin gel. The construct will then be implanted in a cranial window of a
SCID mouse. The vasculogenic potential of the EGFP labeled endothelial cells will be
monitored in real-time with intravital multiphoton laser scanning microscopy. Functional
engineered vessel density will be assessed at various timepoints for the different
experimental groups.
Specific Aim 2c: Determine the in vivo functional performance of endothelial progenitor
cell derived blood vessels
The functional performance of engineered blood vessels will be assessed. Once the
engineered vessels have stabilized, the vascular permeability, response to cytokine
stimulation and blood flow rate will be measured and compared to those of the normal
mouse brain capillaries.
Specific Aim 3: Determine the capacity of mesenchymal stem cells to function as
vascular progenitor for both endothelial and perivascular lineages.
Mesenchymal stem cells (MSCs) are multipotent cells that have potential to differentiate
into a number of different connective tissue lineages including osteocyte, chrondrocyte
and adipocyte. Data in the literature also suggest that mesenchymal stem cells may
function as vascular progenitor cells with the capacity to differentiate into both
endothelial and smooth muscle cells. However, the data are generally equivocal. Here
we will investigate the cellular fate of fluorescently labeled mesenchymal stem cells to
ascertain their vascular potential in vivo.
Specific Aim 3a: Define the expression of endothelial and smooth muscle markers in
mesenchymal stem cells in vitro.
The expression of endothelial and smooth muscle markers in mesenchymal stem cells
will be confirmed with immunostaining and polymerase chain reaction (PCR). Human
umbilical cord vein endothelial cells and human aortic smooth muscle cells will be used
as appropriate positive control. Mesenchymal stem cells will be induced to differentiate
by co-culturing them with mouse endothelial cells. The change in the gene transcription
of human endothelial and smooth muscle markers in MSCs will be quantified by real-
time PCR.
Specific Aim 3b: Determine the in vivo fate ofmesenchymal stem cell implanted alone or
co-implanted with endothelial cells.
Mesenchymal stem cells will be transduced by retrovirus to express EGFP. The EGFP
labeled MSCs will either be implanted alone or co-implanted with DsRed labeled
HUVECs in a collagen gel in a cranial window of a SCID mouse. Similar to Aims 1 and
2, microvascular network derived from the EGFP labeled MSCs will be imaged by multi-
photon laser scanning microscopy. The ability of MSCs to differentiate into either
endothelial cells or perivascular cells will be assessed by their morphology and location
in a blood vessel and their identify will be confirmed by immunohistochemistry.
Specific Aim 3c: Determine the in vivo functional performance of mesenchymal stem cell
derived blood vessels.
The functional performance of the mesenchymal stem cell's derived blood vessels will be
assessed. Specifically, we hypothesize that mesenchymal stem cells will differentiate
into functional pericytes lining a blood vessel and they will respond to physiological
stimulation. The cranial window will be superfused with a solution of endothelin- 1 in
order to induce the contraction of the engineered blood vessels.
Specific Aim 4: Determine the effect of overexpression of PDGF-BB in endothelial cells
on perivascular cells recruitment and blood vessel stabilization
Endothelial cells when implanted alone in a collagen gel in vivo do not form stable
microvascular network. In contrast, co-implantation of endothelial cells with
perivascular precursor cells, such as 10T1/2 cells, allows for the formation of stable
blood vessels. This suggests that endothelial cells alone do not recruit sufficient amounts
of host perivascular cells into a tissue-engineered construct at the critical early timepoint.
To overcome such a problem, we intend to modify the endothelial cells to hasten the
number and kinetics of recruitment of perivascular cells from the host. PDGF-BB has
been shown to be chemotatic for pericyte/smooth muscle cells and endothelial source of
PDGF-BB has been implicated in pericyte recruitment. This study intends to
demonstrate an enhanced recruitment of host perivascular cells by genetically engineered
endothelial cells to overexpress PDGF-BB. Furthermore, the effect of PDGF-BB
overexpression on the stabilization of engineered blood vessels will be investigated.
Specific Aim 4a: Determine the effect of PDGF-BB overexpression on the proliferation
and migration ofpericyte precursor cells in vitro.
Human umbilical cord vein endothelial cells (HUVECs) will be transduced by retrovirus
to express either EGFP or EGFP and PDGF-BB. The amount of PDGF-BB expressed in
endothelial cells will be quantified by enzyme-linked immunosorbent assay (ELISA).
The activity of PDGF-BB expressed in the endothelial-conditioned media will be tested
by their effects on 10T 1/2 cells proliferation and migration.
Specific Aim 4b: Determine the effects of PDGF-BB overexpression in endothelial cells
on the recruitment of host perivascular cells and stabilization of engineered blood
vessels.
PDGF-BB overexpressing HUVECs will be implanted in a collagen gel in a cranial
window of a SCID mouse. Every few days the collagen gel will be imaged with multi-
photon laser scanning microscopy. The functional vessel density will be measured and
compared to the control group (HUVECs expressing EGFP only). To directly observe
the effects of PDGF-BB overexpression on perivascular cell recruitment, the genetically
modified HUVECs will be co-implanted with 10T1/2 cells that have been labeled with
DsRed in a cranial window. The kinetics and extent of perivascular cell recruitment
toward the endothelial cells will be measure and quantified.
Background
The past century has seen a dramatic rise in the life expectancy of Americans from 48
years of age in 1900 to 78 years of age in 2005. Many factors have contributed to such a
dramatic increase, including better diet and personal hygiene and the numerous advances
in modem medicine. The leading causes of death in the early 20th century were
infections. Today, the two leading causes of death for Americans are cardiovascular
disease and cancer. An interesting thing connecting these two seemingly unconnected
diseases is the marked functional abnormality of the blood vessels. In the case of
cardiovascular disease, it is often due to an insufficient blood supply as a result of a
rupture of an atherosclerotic plague or an aberrant growth of smooth muscle cells in the
intimal layer of a blood vessel. One underlying cause of the atherosclerosis is endothelial
dysfunction. In the case of cancer, specifically solid tumor, formation of new blood
vessel drives both the growth and metastatic potential of a tumor[6]. Tumor blood
vessels are also functionally, morphologically and molecularly abnormal[7]. More than
three decades ago Dr. Judah Folkman proposed that tumor blood vessels might serve as a
viable therapeutic target in controlling tumor growth[8]. More recently, this goal has
been realized with the FDA approval of Bevacizumab, a monoclonal antibody that
inhibits vascular endothelial growth factor (VEGF), for treatment of colorectal cancer and
breast cancer. Clinical trials of Bevacizumab has demonstrated efficacy in controlling
local tumor growth and extending patient survival when combined with chemotherapy[9].
It is clear that a better understanding of the normal physiology and pathophysiolgy of the
vascular system would lead to the development of novel treatment for cancer and
cardiovascular disease.
The vascular system
To maintain homeostasis, the body requires a transport network to supply nutrients, to
exchange gas, and to remove waste products and metabolic intermediates from different
tissues in the body. The circulatory system arose during evolution to provide such
functions. The circulatory system is composed of a heart, an arterial network and a
venous network (analogy: a pump, a delivery network and a return network). Working in
parallel with the circulatory system is the lymphatic network that functions to drain
excess tissue fluid and returns them back into the blood circulation. When the circulatory
system goes awry, it can manifest in a number of different diseases. For example, when
blood flow is disrupted in a tissue, the affected tissue undergoes a number of
physiological and pathological changes; a process generally defined as ischemia.
Ischemia induces cellular dysfunctions that thwart the normal function of a tissue, and
depending on tissue type and severity of the ischemia, irreversible damage including cell
death may occur. Ischemia can occur to any tissue, but its effects on the heart have the
highest morbidity and mortality since the circulatory system itself is directly affected.
Once a tissue is injured, it may form scar tissue, self-repair, or a combination of the two
processes. Vascular remodeling is usually involved in the innate repair mechanism.
Examples include the development of collateral circulation in coronary artery disease,
and the angiogenic response following ischemic stroke and myocardial infarction.
Unfortunately, these remodeling responses are often insufficient to overcome the disease,
e.g. the extent of angiogenesis after the initial ischemic stroke is correlated with
improved survival [10], but this post-ischemic angiogenic response is transient and may
be completely abrogated within a few weeks [11]. In the case of myocardial infarction
(MI), significant tissue damage occurs but there may remain viable cells that can regain
function if perfusion is restored. Therapeutic revascularization may facilitate tissue
repair, thus allowing for partial or complete restoration of normal tissue function. This
thesis focuses on developing cell-based technique to create functional blood vessels in
situ for both therapeutic revascularization and tissue engineering.
Developmental Angiogenesis and Vasculogenesis
The cardiovascular system arises during early embryogenesis, when committed
endothelial progenitor cells (known as angioblasts) are fused to form a primitive plexus
of blood vessels, in an event known as "vasculogenesis". The development of the
vascular system is intimately linked to the hematopoietic system. Endothelial cells and
hematopoietic cells share a common origin in being derived from the mesodermal layer.
Blood progenitor cells are first arisen in the yolk sac as blood islands in a process called
primitive hematopoiesis. The outer surface of the blood islands is covered with
angioblasts. Hematopoietic cells derived from primary hematopoiesis do not persist in
the adult hood. The cells that eventually become the hematopoietic stem cells (HSCs) in
the bone marrow are derived from progenitor cells in the aorta-gonad-mesoneprhos
(AGM) region, and this differentiation process is known as definitive hematopoiesis [12].
The HSCs migrate to the fetal liver where they self-renew and differentiate into all
lineages of cells in the hematopoietic system. After birth, the HSCs migrate from the
fetal liver and homes to the bone marrow. Because of the ability of the progenitor cells in
the AGM region to differentiate into both hematopoietic cells and endothelial cells, such
cells are termed the hemangioblasts.
Hemangioblasts have been generated in vitro by differentiating mouse embryonic stem
cells. The cells were shown to be Flk1 (VEGFR2) positive and a single cell can produce
blast colonies that have bipotential of differentiating into hematopoietic and endothelial
cells [13, 14]. The presence of hemangioblasts in adult remains controversial. No studies
have yet unequivocally demonstrate a single adult stem cell can give rise to both
hematopoietic and endothelial cells.
Besides hemangioblast, there may also exist a common progenitor for vascular cells (both
endothelial and smooth muscle lineages). Studies in mouse embryonic stem cells have
demonstrated that flkl+ or isll+ cells are capable of differentiating into either endothelial
or smooth muscle lineages depending on growth factors added in the cell culture
media[15-17]. Addition of VEGF into the media selected for cells of the endothelial
lineage while the addition of PDGF-BB selected for cells of the smooth muscle lineage.
In addition, bone marrow-derived mesenchymal stem cells (MSCs) have also been shown
to express markers of either endothelial cells or smooth muscle cells when
differentiated[18, 19]. This suggests that MSCs may function as an vascular progenitor
cells that exist in an adult.
Following the formation of the vascular plexus, further growth of the vascular system
occurs predominantly through "angiogenesis": the growth of new vessels from pre-
existing vessels. This can occur through sprouting, bridging, or intussusception (Figure
1). The vascular cells organized into hierarchal organization with larger vessels sub-
divided into smaller vessels. The endothelial cells also begin to become specialized by
differentiating into arterial and venous endothelial cells. This sub-specialization occurs
before the onset of blood flow, thus suggesting that endothelial specialization is in part
determined by genetic pre-programming and not solely by environmental cues (ie.
hemodynamics)[20].
Molecular regulators of angiogenesis
Since the blood vascular network is so critical to the health and disease of an organism, it
comes as no surprise that angiogenesis is a highly regulated mechanism involving many
different and interacting molecular pathways. Here, I will review three specific molecules
that are involved in angiogenesis and vessel maturation: VEGF, and PDGF.
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF-A, also often referred to simply as VEGF) is a
master regulator of angiogenesis. There are 5 members in the mammalian VEGF family:
VEGF-A, -B, -C, -D, and placenta growth factor (PlGF). The VEGF family binds to three
receptor tyrosine kinases (VEGF receptor -1, -2, and 3), as well as co-receptors such as
neuropilins.
VEGF-A comes in different isoforms (VEGF204, VEGF189, VEGF165, VEGFl45, and
VEGF121) as a result of alternative splicing. The isoforms differ in the length of their C-
terminal end of the amino acid sequence. The difference manifests in varying capacity of
VEGF isoforms to bind to heparin sulfate on the cell surface and in the extracellular
matrix. VEGFl21 is an acidic protein, does not bind to heparin sulfate and can freely
diffuse in the extracellular matrix. In contrast, VEGF189 and VEGF204 are highly basic
and they bind tightly to heparin sulfate. The high affinity of VEGF189 and VEGF204 to
heparin sulfate results in their sequestration in the extracellular matrix. The consequence
is limited diffusion and biological action of the two isoforms. VEGF165 has intermediate
properties in that it binds to heparin sulfate less tightly, thus allowing it to diffuse in the
extracellular matrix. The dual actions of binding and diffusing in the ECM generate a
concentration gradient of VEGF165 from a secreted source of VEGF (ie. region of
hypoxic tissue). The VEGF gradient is critical in directing angiogenesis spatially. Mice
that have been engineered to express VEGF specific isoform (i.e. VEGF120) succumbed
to perinatal death as a result of impaired angiogenesis [21]. Thus, in using VEGF for
pro-angiogenic therapy, it is critical to select the appropriate VEGF isoform or the right
mixture of VEGF isoforms in generating new blood vessels.
VEGF has a multitude of effects on blood vessels, including increasing vascular
permeability, stimulating endothelial cell proliferation, inhibiting endothelial cell
apoptosis, and enhancing endothelial cell migration. The expression level of VEGF
during vessel development is critical since either a half-fold reduction or a twofold increase
in VEGF expression can lead to lethality to a mouse embryo[22, 23].VEGF expression
level in the adult tissues with a few exceptions is generally low but recent findings
suggest a homeostatic role of VEGF signaling in maintaining normal endothelial
functions. Administering four different VEGF-signaling inhibitors in adult mice, it was
shown that the vascular densities were reduced by 20 to 70% in different tissues ranging
from pancreatic islets to thyroid tissue [24]. The extent of vessel regression was
dependent on the particular organ, but a common feature was that the affected endothelia
were all fenestrated. A previous in vitro study has indicated a role of VEGF in inducing
endothelial fenestration [25]. Upon cessation of VEGF inhibition, the blood vessels were
able to re-grow but the vessel density remained close to 20% less than the vehicle control
40 days after the last treatment [26].
Platelet Derived Growth Factor
PDGF is a member of a super family of homodimeric cytokines including VEGF, and
P1GF [27]. It was initially discovered and purified from degranulating platelets, but
PDGF is now known to be expressed by many different cell types including macrophage,
endothelial cells, fibroblasts, smooth muscle cells, and by a number of tumor [28, 29].
PDGF has dual functions in being both a mitogen for mesenchymal cells including
muscle, bone/cartilage, and other connective tissue cells and a chemotatic agent [29, 30].
The chemotatic function of PDGF, PDGF-B in particular, plays an important role in the
recruitment of perivascular cells to endothelium. Within the PDGF protein family, there
are four different distinct genes (-A, -B, -C, -D) that encode structurally related
polypeptide chains. PDGF-A and -B are the best characterized and they can form homo-
and/or heterodimeric combination resulting in three isoforms of PDGF(-AA,-BB,-AB).
The three isoforms of PDGF have different receptor affinities and thus also differ in their
biological activities.
PDGF-B has been implicated to be involved in vessel maturation. In vitro studies
suggest that PDGF-B is involved in the recruitment of perivascular cells [30]. This has
been further confirmed by genetic knockout model of PDGF-B and PDGFR-13. The two
knockout mice share similar phenotypes in that both mice are embryonic lethal. The
blood vessels in the mice are hemorrhagic and show a reduction in the number of
perivascular cells. When PDGF expression is knocked out specifically in endothelial
cells, it causes abnormality in the blood vessels in the heart, kidney and brain. This
suggests that the secretion of PDGF from endothelial cells is critical during the
development of matured vessels. A recent study has added a layer of complexity - it was
shown that not only is the secretion of PDGF important, but a gradient of PDGF
concentration is necessary for perivascular cell recruitment. PDGF-B contains, at its
carboxyl terminal end, approximately 10 basic amino acid residues that are known as the
retention sequence. It is believed that the retention sequence of PDGF-B interacts with
the negatively charged components of extracellular matrix such as heparan sulfate on the
cell surface. Normally, most of the secreted PDGF-B is retained at the cell surface,
thereby limiting their actions to nearby cells only. Mice that have been genetically
engineered to have PDGF-B deficient in retention sequence exhibit marked abnormality
in the brain blood vessels due to a reduction in perivascular cells [31].
Structure of the blood vessels
Blood vessels follow a fairly consistent basic structure: a tube of endothelial cells
surrounded by perivascular cells and extracellular matrix. The structural organization of
these components depends on the size, location, and function of the associated blood
vessel. For example, endothelial cells in arterioles are always continuous, and are almost
completely enclosed by tightly packed smooth muscle cells, whereas capillaries are only
sparsely covered by pericytes, and capillary endothelial cells may be continuous,
fenestrated, or discontinuous, depending on the specific organ. Proper functional and
structural association between endothelial cells, mural cells and the extracellular matrix is
crucial to the stability and function of blood vessels.
Importance ofperivascular cells
Although endothelial cells initiate the process of angiogenesis, they alone cannot
complete the process. Endothelial cells initially form a naked tube that is highly
permeable and unstable[32]. For vessel maturation and stabilization, the naked
endothelial tube undergoes a series of steps to recruit and to differentiate perivascular
cells to line the outer layer of the vessels[33, 34]. Perivascular cells such as vascular
smooth muscle cells and pericytes are thought to provide structural integrity to the
vessels, lay down the extracellular matrix, and provide necessary survival factors to the
endothelial cells [35].
The importance of perivascular cells can be seen in a number of diseases that is caused by
the lack of pericytes or pericyte dysfunction. Pericyte loss can lead to leaky vessels and
vessel aneurysm. In diabetic retinopathy, injury to pericytes leads to the secondary
change in endothelium that induces pathological angiogenesis. Damage to smooth muscle
cells due to chronic amyloid deposition is also believed to be an early step that ultimately
leads to hemorrhagic stroke [36]. Pericyte is an indispensable partner to endothelial cells
in forming healthy blood vessels. In a model of engineered microvessels, stable and
functional vessels form only in the presence of perivascular cells[37].
To date the emphasis of the pro-angiogenic therapy has been focused almost exclusively
on endothelial cells, with perivascular cells either totally neglected, or treated simply as a
muscular tube to maintain the blood vessel's structure. Engineered blood vessels have
often been found to be immature and unstable [38], and the lack of proper perivascular
cell support is likely to be one of the main reasons for this instability. Recently, our group
has shown that perivascular cells must be appropriately incorporated into the design of
engineered vessels in order to form long lasting, stable vasculature [37]. By co-implanting
human umbilical-vein endothelial cells (HUVECs) with 10T 1/2 cells, a mesenchymal
precursor cell line that is capable of differentiating into perivascular cells through
heterotypic interaction with endothelial cells [39], we were able to produce small
diameter blood vessels that remained patent for over 1 year with good functionality, and
displayed proper coverage of perivascular-like cells.
Therapeutic Angiogenesis
Many methods designed to increase the degree of vascularization are under active
investigation as treatment for ischemic diseases such as myocardial infarction [40] and
stroke [41, 42], with the ultimate goal of relieving ischemia by producing long-lasting,
functional blood vessels at the infarct site. Ideally, the new vessels would form rapidly
(allowing for quick improvement in perfusion), and would resemble normal vessels in
both structure and function. Most of the approaches in pro-angiogenic therapy can be
grouped into two broad categories: 1) growth-factor based approaches where angiogenic
growth factors, such as members of the VEGF or FGF families, are used to induce
angiogenesis from the host; or 2) cell-based approaches where cells forming blood
vessels such as endothelial cells are seeded onto scaffolds and grown under various
conditions. Each approach has advantages and drawbacks.
Angiogenic factors such as VEGF can induce host angiogenesis, and can potentially be
used easily "off the shelf". But growth factors alone may not be sufficient to create
mature and stable vasculature. In a study with injection into normal tissue of an
adenoviral vector expressing VEGF, new blood vessels formed, but these vessels were
highly disorganized, leaky and hemorrhagic [32]. Furthermore, VEGF can potentiate
inflammation by increasing adhesion molecules or releasing chemokines [43-45]. The
duration of the cytokine release may also be important for the formation of stable
vasculature. Two weeks application of VEGF leads to transient formation of
microvasculature that regressed after VEGF withdrawal. In contrast, microvasculature
formed in response to 32 days of VEGF are stable and persists for months after VEGF
withdrawal[46].
Delivery of a single angiogenic factor alone may not be able to induce mature vessel.
Angiogenesis is a tightly controlled physiological process, it requires a constellation of
growth factors expressing at the correct spatial and temporal pattern. Studies have
suggested co-delivery of Ang and VEGF, or PDGF and VEGF can lead to vessels with
higher vascular density and pericyte coverage compared to delivery of individual growth
factor alone[47, 48]. In particular, sequential, controlled delivery of VEGF and PDGF-
BB is able to induce a matured vascular network with vessels having a thick coat of
smooth muscle cells[48]. But it takes more than 2 weeks for host endothelial cells to
infiltrate to the construct; furthermore, the quality and stability of the vessels maybe low
once all the growth factors have released.
Preclinical and Clinical Results of Pro-Angiogenic Therapy
Due to the critical role VEGF plays in angiogenesis, it has been actively investigated for
the treatment of ischemic tissues, where there is often no effective therapy. Variety of
animal models has been developed to test for the efficacy of VEGF in enhancing tissue
perfusion [49]. Two commonly used preclinical models include ischemic heart and
ischemic limb that are induced by the ligation of the coronary or femoral artery,
respectively. In some studies, recombinant VEGF was administered directly and in
others, VEGF gene transfer was achieved by either naked DNA or adenoviral vector. In
a rabbit model of hindlimb ischemia, single administration of recombinant human
VEGF165 enhanced tissue perfusion and the development of collateral vessels [50].
Similar results were obtained with gene transfer of cDNA encoding VEGF isoforms [511.
Based on the encouraging preclinical data, VEGF administration has been tested in
patients with limb or myocardial ischemia. The results from double-blind randomized
placebo-controlled trials so far have proven that protein infusion or gene transfer with
VEGF is safe and generally well-tolerated but none of the studies convincingly showed
improvement in tissue perfusion or cardiac function with treatment 152-55].
The failure in the clinical trials could be related to the a number of issues including the
choice and pharmacokinetics of biological agents, responsiveness of tissue to exogenous
angiogenic factors, and the selection of patients 156]. All the clinical trials to date have
used single agents and this fails to take into account of the complexity of the myriad
molecular pathways governing vessel growth. VEGF is an initiator of angiogenesis since
it guides the sprouting of endothelial tip cells from pre-existing vessels but an orchestra
of molecular signals is necessary for the process of vessel maturation [39, 57]. The
growth factors may need to be supply in a temporal and spatial dependent manner [31,
58]. Almost invariably, the preclinical animal models have been tested on young and
healthy animals that respond robustly to the angiogenic factors. In contrast, the clinical
trials were performed on old and diseased patients that are refractory to maximum
tolerated medical treatment [59]. Vascular response to angiogenic factors is reduced with
age, hyperglycemia and atherosclerosis [56]. Patients with diabetes mellitus or elevated
homocysteine exhibited impaired angiogenic response [60, 61]. The above factors may
affect the clinical efficacy is the use of VEGF as single agent in enhancing development
of collateral vessels for treatment of ischemic tissues.
Cell-based Therapy
Another strategy in forming a vascularized bed is to introduce the necessary blood vessel
components-endothelial cells and/or perivascular cells directly to the tissue engineered
construct. The implanted cells can potentially generate new vascular network formation
in two ways: i.) directly by aggregating and anastomosing to the host vessels, or ii.)
indirectly by inducing angiogenesis in the host tissue through the release of angiogenic
factors. Studies have shown that implantation of human telomerase reverse transcriptase
(hTERT) transduced human dermal microvascular endothelial cells(HDMECs) or Bcl-2
transduced human umbilical cord vein endothelial cells(HUVECs) subcutaneously in
SCID mice can lead to functional vessel formation[38, 62]. Endothelial cells and smooth
muscle cells have also been shown to express an array of angiogenic factors in vitro[63].
Thus, the implanted vascular cells may induce neovascularization by a combination of
the two methods. Irrespective of the mechanism, new blood vessel formation is essential
since blood flow is required for tissue survival. The ideal pro-angiogenic therapy would
induce rapid formation of vessel thus, allowing for quick resumption of blood flow. The
new vessels would resemble normal vessels in such properties as permeability, vessel
geometry, vessel diameter distribution, etc.
Cell-based therapy is currently evaluated in the clinics for treatment of myocardial
infarction. Generally, the procedure consists of the isolation of adult stem cells or
progenitor cells from peripheral blood or bone marrow and the injection of these cells to
the infracted region of a heart. A number of studies in both pre-clinical and clinical
settings has demonstrated a benefit of the adult stem cell treatment by showing an
improvement in cardiac functions post-MI compared to placebo [64-69]. While these
results are encouraging, cellular therapy suffers from the scarcity of cell source, as well
as potential unpredictability in the implanted cells' behavior.
Circulating Endothelial Progenitor Cells
The formation of new blood vessels in adult was thought to occur exclusively through the
process of angiogenesis, where the newly formed vessels are derived from pre-existing
blood vessels [70, 71]. The alternate process, vasculogenesis, in situ formation of blood
vessel from endothelial progenitor cells, was thought to occur only during development
[72]. The discovery of circulating endothelial progenitor cells along with the subsequent
in vivo studies of their functions caused a paradigm shift.
The presence of endothelial cells in circulation has been speculated for almost 100 years,
but only recently has the existence of such cells been established with the aid of modem
techniques [73, 74]. In 1997, Asahara et al. isolated circulating endothelial progenitor
cells from human peripheral blood and demonstrated in vitro and in vivo their endothelial
characteristics [75]. CD34+ mononuclear blood cells, sorted from peripheral blood and
cultured on fibronectin-coated flasks, gave rise to adherent cell clusters with cobblestone
morphology. The attached cells were characterized as endothelial cells by their ability to
uptake AcLDL and the expression of a range of endothelial markers including CD3 1,
VEGFR-2 and Tie-2. To test for the in vivo function of the EPCs, freshly isolated CD34+
cells were injected intravenously into mice with experimental model of ischemic limb.
The CD34+ cells were shown to participate actively in angiogenesis in the ischemic
tissue. However, questions remain on the contribution and duration of the injected cells to
the vascular network.
The origin and nature of EPCs have remained controversial. EPCs have been defined as
derived from bone marrow and that they actively participate in forming new blood
vessels in vivo. Isolated EPCs are characterized by their expression of CD 133, CD34,
and VEGFR, their binding to Ulex Europeus lectin, and their ability to uptake AcLDL.
However, there is a separate population of endothelial cells, circulating endothelial cells
(CECs), that are in the blood besides EPCs [76]. CECs are believed to be matured
endothelial cells that have shed into the blood stream under pathological settings. Recent
studies have also suggested monocytes, when cultured in vitro, may upregulate the
expression of endothelial markers and downregulate the expression hematopoietic
markers [77, 78]. The in vivo assay thus far of injecting EPCs intravenously to home to
tumor tissue or ischemic tissue left many unanswered questions. First, how readily do the
ex vivo expanded EPCs form functional vessels when implanted in vivo? Second, if the
ex vivo expanded EPCs do form functional vessels in vivo, how well do these vessels
perform? Third, EPCs have been isolated and cultured from both adult peripheral blood
(PB) and cord blood (CB); which source of EPCs is better at vascularizing tissue. Such
information is both necessary and required before EPCs are to be widely used in
regenerative medicine.
Alternatively, a renewable and potentially unlimited source of endothelial cells can be
generated from human embryonic stem cells (hESCs). Human embryonic stem cells are
pluripotent, capable of differentiating into all cell types in a body. They also have the
advantage of having unlimited proliferation potential. However, there are some
significant scientific challenges in using hESCs in the clinics. First, the right
differentiating condition (i.e. growth factors, oxygen tension, extracellular matrix, etc.)
needs to be identified for derivation for each cell type. Second, there are risks in the
formation of teratoma with undifferentiated hESCs.
Bone Marrow Derived Mesenchyaml Stem Cells
Mesenchymal stem cells are multipotent cells that reside in the bone marrow, vessel wall,
and adipose tissue[79]. MSCs are true stem cells in that they are undifferentiated cells
with the capacity to both self-replicate and self-renew. By culturing MSCs under specific
culturing conditions (varying level of hormone, and cytokines), they can differentiate into
specific cell lineages of the connective tissue including adipocyte, osteocyte, and
chrondrocyte[80]. MSCs can be isolated from bone marrow mononuclear cells by their
propensity to adhere and grow on culture plastic[81]. Analysis of surface receptors on
MSCs suggests that they express Stro-1 and CD105 but are negative for CD34 and
CD31 [81, 82]. Due to the multipotential nature and proliferative capacity of MSCs, they
are actively being investigated for clinical use. MSCs have be used to engineer bone
tissue for reconstructive surgery[83]. In animal model of myocardial infarction, injection
of MSCs has been shown to limit infarct size and improve cardiac functions[68, 69].
Histological analysis reveals that MSCs have differentiated into cardiac myocytes,
smooth muscle cells, and endothelial cells[84]. MSCs may also help to revascularize the
infracted heart tissue through expression of high level of VEGF[85, 86].
Potential ofMesenchymal Stem Cells as Perivascular Cells
Smooth muscle progenitor cells can be isolated from bone marrow stromal cells and they
are found to be positive for PDGF-[ receptor[87]. In vitro culture of mesenchymal stem
cells shows smooth muscle cell phenotype with the expression of ca-smooth muscle
actin[88]. In response to TFG-31, MSCs upregulate the expression of ca-smooth muscle
actin and increase in contractility [89]. In vivo evidence has also accumulated to support
the hypothesis that MSCs have the ability to differentiate to smooth muscle cells. Recent
studies have suggested the existence of a population of bone marrow cells that can give
rise to circulating smooth muscle progenitor cells [87, 90]. Bone marrow derived smooth
muscle progenitors have been found to contribute to the perivascular layer of blood
vessels in pathological settings including age atherosclerosis and graft intimal
hyperplasia[91-94]. Whether bone marrow derived cells can differentiate into
perivascular cells in physiological setting remains unclear.
Potential of MSCs in Differentiating into Endothelial Cells
Mesenchymal stem cells may be a true vascular progenitor; being able to differentiate
into both endothelial cells and perivascular cells. A recent report shows that culturing
MSCs with high level of VEGF in vitro can upregulate expression of endothelial markers
including VEGFR-1 and VEGFR-2[19]. The MSCs derived endothelial cells are also
positive for von Willebrand factor. In vivo studies also suggest that MSCs may
differentiate into endothelial cells. When MSCs are injected into cardiac tissue, they
become positive for CD31 and von Willebrand factor and form vascular structure[69, 84,
95]. Whether the transition of MSCs into endothelial-like cells occurs through
differentiation or cell fusion[96] remains unclear.
This thesis will address the outstanding questions on the vasculogenic potential of
endothelial progenitor cells, mesenchymal stem cells and human embryonic stem cells by
the use of intravital microscopy coupled with fluorescence labeled cells in a chronic
animal window model. In addition, this thesis examines the combined use of angiogenic
factor-based and cell-based therapy in evoking a synergy in generating functional blood
vessels.
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Abstract
Human embryonic stem cell (hESC) lines provide a unique system for studying human
embryonic development and have enormous potential as a source of therapeutic tissues,
including ES cell-derived vascular and hematopoietic lineages. However, it is difficult to
generate a large-scale relatively pure population of specific lineage cells derived from
hESCs. Here, we describe a novel 2-dimensional culture system without intermediate
embryoid body formation for hESC differentiation into hematopoietic and endothelial
cells. HESCs generated CD34+ cells that could under specific conditions differentiate
into either hematopoietic or endothelial cells. Hematopoietic differentiation was induced
by stem cell factor (SCF) and Flt-3 ligand (Flt3L) whereas, VEGF promoted endothelial
cell differentiation. When the embryonic endothelial cells were implanted into SCID
mice, they formed functional blood vessels in vivo that connected to the host vascular
system and were durable conduits for blood for greater than 150 days. This system paves
the way for further large-scale, therapeutic generation of human hematopoietic and
endothelial cells derived from ES cells.
Introduction
Mouse embryonic stem (ES) cells have been studied extensively in murine
embryogenesis. However, the lack of experimental cell systems has made it difficult to
study many developmental processes in humans. Human embryonic stem cell (hESC)
lines provide not only a unique system for studying human embryonic development, but
also have enormous potential as a source of therapeutic tissues, including those of
vascular and hematopoietic lineages. In vitro, hESCs can be triggered to undergo
spontaneous differentiation by forming 3-dimensional (3D) embryoid bodies (EBs)
containing many different cell types [1], including hematopoietic cells [2-4] and
endothelial cells [5]. Although the EB is far less organized than an actual embryo, it can
partially mimic the spatial organization in the embryo [6]. However, unlike mouse ES
cells, in which a single cell is able to form an EB in specific conditions, the formation of
EBs from hESCs is inefficient and usually requires a whole colony of hESCs. Dispersed
single human ES cells cannot aggregate efficiently to form EBs, and a large amount of
cells undergo cell death during EB formation [7]. Therefore, one of the challenges for
stem cell research is to obtain sufficient differentiated cells.
Material and Methods
Human embryonic stem cell cultures
The hESC lines, H1 and H9 [8], were obtained from WiCell Research Institute (Madison,
WI). HESCs (passages 29-50) were grown on mouse embryonic fibroblasts (MEFs),
which were inactivated with irradiation or mitomycin C-treatment in hESC medium
containing DMEM/F 12, 20% knockout serum replacement, 1 mM L-glutamine, 0.1 mM
nonessential amino acid (all from Invitrogen), 0.1 mM 3-mercaptoethanol (Sigma), and 4
ng/ml human FGF-2 (R&D Systems). The feeder-free culture on Matrigel (BD
Biosciences) with MEF-conditioned medium (CM) was carried out as described [9].
MEF-CM was filtered through a 0.22 ýtm sterile membrane and stored at >-200 C.
HESC differentiation:
To induce 3-D embryoid bodies (EBs), the hESC colonies were treated with 2mg/ml
dispase for 15 minutes at 370C to loosen colonies; and the colonies were transferred into
ultra low-attachment plates (Corning Incorporated) for EB formation. EBs were cultured
in differentiation medium consisting of IMDM, 15% defined-FBS (Hyclone), 450 ýtM
monothioglycerol (Sigma), 2 mM L-glutamine, 50 U/ml penicillin, and 50 [tg/ml
streptomycin for 10 days with medium change every 2-3 days. For 2D differentiation,
undifferentiated hESCs were given differentiation medium as above for 10 days, and the
medium was changed every 2-3 days.
After 10 days of differentiation in either 2D or 3D culture, single-cell suspensions were
made from differentiated hESCs by treatment with 2 mg/ml collagenase B (Roche) for 20
minutes at 370C, followed by treatment with cell dissociation buffer (Invitrogen) for 10
minutes at 370C. The cells were dissociated by gentle pipetting, and passaged through a
40 ýtm cell strainer (BD Biosciences).
Hematopoietic and endothelial differentiation
CD34+ cells were isolated from differentiated hESCs by using MACS MicroBeads
columns (Miltenyi Biotec), according to the manufacturer's instructions. As determined
by flow cytometry, the purity of isolated CD34+ cells was generally 60-80% at a single
column, and > 95% after the second column. Isolated CD34+ cells were seeded on
gelatin-coated plates (2x10 4 cells/cm 2) in EGM2 medium supplement with or without
hematopoietic growth factors, 100 ng/ml hSCF, and 100 ng/ml hFlt3 ligand. In some
cases, the CD34+ cells were cultured in differentiation medium with the hematopoietic
growth factors, 100 ng/ml hSCF and 100 ng/ml hFlt3 ligand, or the endothelial growth
factor, 50ng/ml hVEGF 165 (R&D Systems) or both. After 7-10 days of incubation, the
suspension cells were harvested for analyses. The adherent cells were harvested by
trypsin treatment and used for analyses.
Flow cytometry and immunostaining
The cells were prepared in PBS containingl% FBS and 0.25% human IgG, and were
labeled for 15-30 minutes at 40C with a combination of monoclonal antibodies (mAbs):
CD31-PE, CD34-APC, CD45-FITC (all from BD PharMingen), Glycophorin A-PE
(Immunotech), and Flkl-PE (R&D system). The samples were analyzed on a
FACSCalisbur (Becton Dickson). Data analyses were performed using CellQuest and
FlowJo software.
For staining, the cells were fixed with methanol for 5 minutes at -200C or with 4%
paraformaldehyde in PBS at room temperature for 15 minutes. The fixed cells were
incubated with 4% goat serum for 30 minutes to block nonspecific binding, and stained
for 1 hour with the primary antibodies: SSEA-1, SSEA-4, TRA-1-60, and TRA-1-81 (all
from Chemicon International Inc), CD31, VE-cadherin, respectively. The secondary
antibody, FITC-conjugated rat anti-mouse antibody (BD PharMingen) was added, and the
cells were incubated for 30 minutes.
For the LDL uptake assay, the cells were incubated with 10 ug/ml of diI-acetylated low-
density lipoprotein (Di-LDL, Molecular Probes) for at least 4 hours. After washing twice
with PBS, the cells were examined under a fluorescence microscope.
Matrigel assay
The assay was carried out essentially as previously described [10, 11]. Twenty four-well
plates were coated with 200 pl/well matrigel matrix (BD Biosciences) at room
temperature for more than 30 minutes. The CD34+ cell-derived endothelial cells (1-5 x
104 cells) were trypsinized and replated onto matrigel plates in differentiation medium at
370 C in 5%CO2. The structures were photographed under phase-contrast microscope
(Nikon) after 16 hours of incubation
Tissue engineered blood vessels
To generate hES cell-derived endothelial cells, human ES cell-derived CD34+ cells were
cultured in either EGM-2 medium or differentiation medium with 100 ng/ml rhVEGF for
7 to 10 days. One million endothelial cells and 200,000 10T1/2 cells were suspended in 1
ml solution of rat-tail type 1 collagen (1.5 mg/ml) (BD Biosciences, Bedford, MA) and
human plasma fibronectin (90 [tg/ml) (Sigma) in 25 mM Hepes (Sigma) buffered EGM
medium at 40 C. The pH was adjusted to 7.4 by using IN NaOH (Fisher Science, NJ). The
cell suspension was pipetted into 12-well plates (Falcon) and warmed to 370 C for 30
minutes to allow polymerization of collagen. Each solidified gel construct was covered
by one ml of warmed EGM medium. After one day culture in 5% CO 2, a skin puncher
was applied to create circular disk-shape pieces of the construct (4-mm diameter), and
they were implanted into the cranial windows in SCID mice [12, 13]. Multiphoton laser-
scanning microscopy was used to visualize and quantify the morphological changes of
EGFP-expressing hESC-derived endothelial cells. The perfused vessels were highlighted
by tail vein injection of 1% tetramethylrhodamine-labeled dextran (MW 2000,000),
indicating the formation of functional engineered vessels [12, 13]
Results and Discussion
To achieve large scale differentiated cells from hESCs, we developed a 2-dimensional
(2D) culture system to differentiate hESCs into hematopoietic and endothelial lineages
(Figure 2.1a). Human ES cells were maintained on mouse embryonic fibroblasts (MEFs)
in the presence of FGF-2, to maintain an undifferentiated state that was confirmed by the
high expression of SSEA-4, TRA-1-60, and TRA-1-80, but not SSEA-1. It was
demonstrated that hematopoietic commitment of hESC differentiation from EBs is
around day 10 [14]. To initiate differentiation, hESCs were placed in differentiation
medium containing defined-FBS for 10 days without supplementation of additional
growth factors. Gene expression analysis of 2D differentiation indicated that the
pluripotent gene, Oct-4, was decreased, and genes for hematopoietic cells (GATA-2) and
endothelial cells (CD31) were increased (Figure 2.1b), which suggests that differentiated
hESCs contain hematopoietic and endothelial progenitors. Compared to 3D EB
formation, 2D differentiation was able to generate robust numbers of differentiated cells
(5- to 10-fold higher) (Figure 2.1c).
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Figure 2.1. Differentiation of human ES cells in 2D culture.
Schematic representation of hESC culture. HESCs were cultured in IMDM differentiation
medium containing 15% defined-FBS for 10 days (a). The CD34+ cells were isolated by
MACS columns, and cultured in the presence of angiogenic or hematopoietic growth
factors or both for an additional 7 to 10 days for endothelial and hematopoietic
differentiation. RT-PCR analysis of CD31 and GATA-2 gene expression in differentiated
hESCs (b). RNA samples were harvested at day 0, day 5, and day 9 of differentiation.
Differentiation potential of 2D and 3D (EB) culture (c). Undifferentiated hESCs were
induced to differentiate in either 2D or 3D cultures for 10 days. The single cell suspensions
were generated as described. The total differentiated cell numbers were calculated based on
the same numbers of input undifferentiated hESCs. The results reflect the mean (+/-SD)
number of total differentiated hESCs from three experiments.
HESCs tend to differentiate in a heterogeneous manner. One of the scientific challenges
in hESC research is to define culture conditions or growth factors to generate a single cell
type from hESCs. During embryogenesis, hematopoiesis is highly coordinated with
vasculogenesis. Hematopoietic and endothelial precursors originate from a cluster
formation of blood islands, consisting of endothelial progenitors and hematopoietic
progenitors [15-17]. These progenitors may be derived from a common precursor, the
hemangioblast. In order to generate both hematopoietic and endothelial populations, we
attempted to isolate hematopoietic and endothelial progenitors, and further induce their
differentiation by exposing the progenitors to lineage-specific growth factors.
CD34+ cell populations in adult human peripheral blood, bone marrow, and cord blood
contain both hematopoietic progenitors and endothelial progenitors [18, 19]. HESC-
derived CD34+ cells, that were produced in co-culture on OP9 stromal cells, had multi-
lineage hematopoietic potential [4]. Here, we investigated whether hESC-derived CD34+
cells contain both hematopoietic and endothelial progenitors. During hESC
differentiation, CD34 expression increased, and -5-8% of the cells were CD34+ by day
10, as indicated by fluorescence-activated cell sorting (FACS) analysis (Figure 2.2a).
Although FACS sorting usually results in purer populations of cells, the frequency of
viable cells was very low when FACS sorting was employed. In order to establish a more
efficient method to isolate CD34+ cells, we used Magnetic Cell Sorting (MACS)
columns (Miltenyi Biotec). The cells from 10-day cultures of 2D-differentiated hESCs
were treated by collagenase B, and the dispersed single cells were immunosorted by
MACS MicroBead columns with the antibody to CD34 (Miltenyi Biotec). The purity of
CD34+ cells ranged from -60-80% after one column selection (Figure 2.2a). CD34+
cells were enriched to 80-95% after a second column selection (Figure 2.2b). The
isolated CD34+ cells were CD45-, and the majority of CD34+ cells expressed CD31
(>60%) (Figure 2.2a). Even though the percentage of CD34+ cells was similar in 2D and
3D cultures, a significant increase of CD34+ cells (5-8 fold) was generated from 2D
cultures because of the increase in total differentiated cells in the 2D cultures (Figure
2.2b). Our results suggest that neither EB formation nor co-culture with stromal cells is
required to generate hESC-derived CD34+ progenitor cells.
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To test whether immature CD34+ cells derived from hESCs contain a progenitor
population that is capable of differentiating into endothelial and hematopoietic cells, we
cultured hESC-derived CD34+ cells in the presence of hematopoietic growth factors,
stem cell factor (SCF) and Flt-3 ligand (Flt3L), or in the presence of the endothelial
growth factor, VEGF, or both. After an additional 7-10 days in culture, both suspension
and adherent cells emerged (Figure 2.3a). The number of suspension and adherent cells
was dependent on growth factors in the culture medium. When CD34+ cells were
cultured in the endothelial medium, EGM-2, the majority of cells (90%) were adherent.
Addition of hematopoietic growth factors to EGM-2 medium increased the number of
suspension cells significantly (Figure 2.3b). Similar results were observed in IMDM
culture media, in which the addition of SCF and Flt3L increased suspension cell number,
and the addition of VEGF and FGF-2 increased adherent cells. To confirm the
hematopoietic nature of the suspension cells, the suspension cells and the adherent cells
were analyzed on methylcellulose cultures for hematopoietic colony formation. The
suspension cells generated significantly more hematopoietic colonies than the adherent
cells (Figure 2.3c). FACS analysis indicated that the pan-hematopoietic marker, CD45,
was enriched in the suspension cells, compared with the adherent cells (Figure 2.3d).
These results suggest that the suspension cells derived from CD34+ cells are enriched in
hematopoietic cells.
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Figure 2.3. CD34+ cells gave rise to populations of adherent and suspension cells
Differentiation of CD34+ cells is dependent on growth factors in the culture system (a).
The addition of angiogenic growth factors, VEGF and FGF-2, promoted the growth of
adherent cells with a spindle-shaped morphology; whereas the addition of hematopoietic
growth factors, SCF and Flt3-L, promoted the growth of suspension cells. Scale bar = 20
tm. Cell number of adherent and suspension cells cultured in EGM-2 medium (b). The
addition of SCF (100 ng/ml) and Flt3-L (100 ng/ml) into EGM-2 medium increased the
number of suspension cells. Triplicate wells of resulting cells were analyzed on day 10 of
cultures. Isolated CD34+ cells were cultured in the presence of hematopoietic growth
factors for 10 days and the suspension cells and adherent cells were assayed separately for
their potential to generate multi-lineage hematopoietic colonies in methylcellulose cultures
(c). Suspension and adherent cells were analyzed by flow cytometry for CD45 expression
(d). CD45 is a cell surface marker for hematopoietic cells. Flow cytometric data are
representative from three independent experiments.
CD31 and VE-cadherin (VE-cad) are markers for human embryonic-endothelial cells [5].
To examine whether adherent cells generated from hESC-derived CD34+ cells express
endothelial cell markers, the isolated CD34+ cells were cultured in the presence of VEGF
for 7 days, and the adherent cells were analyzed for the expression of CD31 and VE-cad
by immunohistochemistry. Both CD31 and VE-cad were present at the endothelial
adherent-type junctions (Figure 2.4a). Dil-acetylated low-density lipoprotein (Di-LDL)
up-taken assays, which have been used to characterize endothelial cells [20], were
performed to confirm an endothelial-like phenotype of CD34+ cells grown in cultures.
Most of these cells incorporated Di-LDL, while neither cultured CD34- cells nor
suspension hematopoietic cells incorporated Di-LDL (Figure 2.4b). The hESC-derived
endothelial cells were then plated on Matrigel, and they rapidly formed vascular network-
like structures (Figure 2.4c), while suspension cells were unable to do so.
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Figure 2.4. Endothelial differentiation of hESC-derived CD34+ cells.
Isolated CD34+ cells were cultured in the presence of angiogenic growth factors for 10
days. Adherent cells expressed the endothelial markers, VE-cadherin and CD31, which
were determined by immunohistochemistry (a), were positive for Dil-AcLDL uptake (b),
and formed vascular-like network on Matrigel (c). Scale bar = 100 tm (a,b), Scale bar =
125 [m (c).
Implanting a PLLA/PAGA polymer scaffold seeded with CD31+ endothelial cells
derived from human ES cells into SCID mice has been shown to result in microvessels
positive for human cells [5]. It was unclear how long these microvessels last in vivo, and
whether the microvessels were connected to the mouse vascular system, though red cells
were seen within them.
To test whether hESC-derived endothelial cells from CD34+ cells were able to form
functional blood vessels in vivo, we studied their behavior in a SCID mouse model that
allows us continuous observation of the engineered vascular network in vivo [12, 13].
Isolated CD34+ cells from GFP-H1 cells were expanded, and matured in the presence of
Adhet t ell Supesoncel
VEGF for 7 days to generate hESC-derived endothelial cells. These cells were mixed
with rat-tail type I collagen to form 3D collagen gels, and implanted into cranial windows
in SCID mice. As an initial test of endothelial cells in vivo, we implanted a collagen gel
that contained both hESC-derived endothelial cells (GFP+) and HUVECs (without GFP).
The GFP+ network-like vascular structures were observed as early as 5 days after the
implantation of endothelial cells (Figure 2.5). After 13 days of implantation, large
vacuoles appeared in the vessel tubes (Figure 2.5). To test whether the engineered
vascular networks connected to the mouse circulatory system to carry blood,
tetramethylrhodamine-labeled dextran was injected into the tail veins. By using a
multiphoton laser-scanning microscopy, the perfused vessels were visualized, suggesting
the formation of functional engineered vessels (Figure 2.5). The hESC-derived vessels in
animals were continuously monitored for prolonged intervals through the cranial
windows. The perfused vessels persisted, and were observed for at least 150 days.

One of the challenges in hESC research is to generate sufficient differentiated cells from
EBs. Our results show that hESCs in 2D cultures were able to generate differentiated
cells with high efficiency. HESC-derived CD34+ cells have both hematopoietic and
endothelial differentiation capacity though it is not clear that this occurs at a clonal level.
Therefore we cannot conclude that there is or is not a hemangioblast population in that
cell fraction. Our studies clearly demonstrate that human embryonic stem cell-derived
endothelial cells were capable of forming functional blood vessels in animals. This
unique differentiation system may provide a renewable resource of endothelial cells for
potential applications, such as engineering new blood vessels for the treatment of
regional ischemia. Our next goal will be to generate hESC-derived hematopoietic and
endothelial cells with animal product-free conditions to further the potential clinical
application of this process.
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Abstract
Tissue engineering requires formation of a de novo stable vascular network. Because of
their ability to proliferate, differentiate into endothelial cells and form new vessels,
blood-derived endothelial progenitor cells (EPCs) are attractive source of cells for use in
engineering blood vessels. However, the durability and function of EPC-derived vessels
implanted in vivo are unclear. To this end, we directly compared formation and functions
of tissue-engineered blood vessels generated by peripheral blood- and umbilical cord
blood-derived EPCs in a model of in vivo vasculogenesis. We found that adult peripheral
blood EPCs form blood vessels that are unstable and regress within three weeks. In
contrast, umbilical cord blood EPCs form normal-functioning blood vessels that last for
more than 4 months. These vessels exhibit normal blood flow, perm-selectivity to
macromolecules and induction of leukocyte-endothelial interactions in response to
cytokine activation similar to normal vessels. Thus, umbilical cord blood EPCs hold great
therapeutic potential and their use should be pursued for vascular engineering.
Introduction
The discovery of circulating endothelial progenitor cells (EPCs) in peripheral blood-
reported almost a decade ago[l]-has generated impetus for using EPCs in applications
ranging from alleviation of tissue ischemia to cancer therapy. One such application is
vasculogenesis- an important objective for tissue engineering. However, in vitro
phenotypic studies have demonstrated that cells defined as EPCs consist of a
heterogeneous population, containing cells with differential phenotype (i.e., endothelial
and hematopoietic myeloid cells) and outgrowth potential[2, 3]. Recent reports have also
shown that peripheral blood (PB)- and cord blood (CB)-derived EPCs (also referred to as
endothelial colony-forming cells[2]) can form functional blood vessels when implanted in
vivo, however the duration and functional performance of these blood vessels have not
been defined[2, 4, 5]. In this report, we address two critical outstanding questions
regarding the use of EPCs for vasculogenesis in tissue engineering. First, can both adult
PB- and CB-derived EPCs form stable vessels? Second, if ex vivo expanded EPCs form
durable vessels in vivo, how well do these vessels function compared to the pre-existing
microvasculature? To this end, we utilized an in vivo engineered vessel model to compare
the neo-vasculature generated by PB- and CB-derived EPC through vasculogenesis. We
assessed the functional performance of the engineered vessels by measuring three
parameters: red blood cell velocity, vessel permeability to serum albumin and leukocyte
rolling in response to cytokine stimulation.
Materials and Methods
Cell isolation and culture
Adult buffy coat samples were obtained from the blood bank at Massachusetts General
Hospital. Umbilical cord blood samples were obtained from the Pediatric Research
Institute, University of St. Louis, MO, according to guidelines established by the Human
Investigation Committee (IRB Protocols#2003-P-000588). The mononuclear blood cells
(MNBCs) were isolated and cultured as described previously with minor
modifications[6]. Briefly, mononuclear cells were isolated by centrifugation over Ficoll
plus density gradient solution. The MNBCs were then cultured on collagen I coated dish
(BD Bioscience, Bedford, MA) with EGM-2MV medium (Cambrex, Walkersville, MD)
supplemented with 10% fetal bovine serum. The medium was changed every 2 to 3 days.
Once endothelial colonies were formed, the cells were then passaged and transduced with
retrovirus vector encoding enhanced green fluorescent protein (EGFP) gene, as
previously described[7]. All experiments were performed with cells less than 6 passages.
C3H10T1/2 (10T1/2) (American Type Culture Collection, Manassas, VA) were grown
and maintained in Eagle's Basal medium (BME) (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum (FBS) and 2mM L-glutamine.
Immunohistochemistry
PB- and CB- EPCs were grown on chamber slides until confluent. The cells were
washed with phosphate buffered saline (PBS) and then fixed by incubating them in ice-
cold methanol for 30 minutes. The chamber slides were then washed with PBS to
remove all traces of methanol. To block non-specific binding, the chamber slides were
incubate in PBS with 3% bovine serum albumin (BSA) for 1 hour followed by overnight
incubation with primary antibodies at 40C. The following primary antibodies were used
at 1:200 dilution: CD31 (Dako), VE-Cadherin (Pharmingen), von Willebrand Factor
(Dako), Tie-2 (R&D Systems), and Ki-67 (Dako). The next day, the chamber slides were
washed with PBS and incubated with appropriate Cy3-conjugated secondary antibodies
(Jackson ImmunoResearch). The chamber slides were then washed and mounted in
Vectashield containing DAPI (Vector Laboratories).
Mice with CB-EPCs implanted in a gel in the cranial window were sacrificed and
immediately perfused with 4% paraformaldehyde intracardially to remove the red blood
cells and to fix the tissue. The gels were then extracted and incubated in 4%
paraformaldehyde for 3 hours and then washed with PBS. The gels were initially
blocked for endogenous mouse IgG with Vector Mouse on Mouse Kit (Vector
Laboratories) for two hours following manufacturer's protocol. The gels were then
incubated overnight at 40C in blocking solution containing 3% BSA, 5% normal rabbit
serum, and 0.3% Triton Xl00 in PBS. The next day, primary antibodies (CD31 (Dako)
and VE-Cadherin (Pharmingen)) were diluted in blocking solution at a dilution of 1:400
and were added to the gel. After overnight incubation with primary antibodies at 40C, the
gels were washed extensively with PBS to remove the unbound antibodies. The gels
were then incubated with Cy3-conjugated rabbit anti-mouse secondary antibodies at
1:400 dilution for 3 hours at room temperature. After washing with PBS, the gels were
mounted in Vectashield and imaged with confocal microscope.
Apoptosis assay
PB- and CB-EPCs were grown in chamber slides to confluent. The chamber slides were
then washed with PBS to remove all traces of serum and growth factors. EGM2 basal
media containing no serum or growth factors were then added to the chamber slides.
After 48 hours of incubation, the chamber slides were then washed with PBS and fixed in
ice-cold methanol for 30 minutes. The EPCs were then assay for apoptotic cells with
ApopTag@ Red In Situ Apoptosis Detection Kit (Chemicon) following manufacturer's
protocol.
Preparation of tissue-engineered vessel construct
The EGFP-labeled endothelial progenitor cells (EGFP-EPCs) and 10T1/2 cells were co-
cultured in a collagen gel and implanted onto a mouse cranial window (6 to 8 weeks old
male SCID mice) as previously described[7]. One million EGFP-EPCs (EPC-alone
group) or 1 x 105 EGFP-EPCs and 2 x 105 of 10T1/2 (EPCs + 10T1/2 co-implantation
group) were suspended in 1 ml solution of rat-tail type 1 collagen (1.5 mg/ml) (BD
Biosciences, Bedford, MA) and human plasma fibronectin (90 [tg/ml) (Sigma) in 25 mM
Hepes (Sigma) buffered EGM-2MV medium at 40 C. pH was adjusted to 7.4 by using 1N
NaOH (Fisher Science, NJ). The cell suspension was pipetted into a single well of a 12
well plates and warmed to 370 C for 30 min to allow polymerization of collagen. Once the
collagen gel had solidifed, one ml of warmed EGM-2MV medium was added into the
well and the cell culture plate was then placed overnight in a incubator maintained at
370 C and 5% CO2. The next day, a skin puncher (4-mm diameter) was applied to the
collagen gel construct to create a circular piece and it was then implanted into a cranial
window of a severe combined immunodeficient (SCID) mice.
Visualization and analysis of tissue-engineered vessels
The fate of the EGFP-labeled endothelial cells in vivo was tracked by intravital imaging
with multi-photon laser scanning microscopy at various time points[8]. Functional blood
vessels were revealed by intravenous injection of 100 [tl of tetramethylrhodamine-
conjugated dextran (2,000,000 MW at 10mg/ml) via tail-vein. The same region of the gel
was tracked at different time points for consistency. The perfused vessel length density
was quantified by manual tracing of perfused blood vessels lined by EGFP-EPCs with a
macro developed in-house in Matlab. For each animal, three stacks of images (333 [tm
by 250 rtm) were taken at 5 [tm interval in the z direction and an average gel thickness
around 80 [tm. For consistency, we chose to analyze the middle section of the gel by
projecting the maximum intensity of the middle five stacks (20 ýtm in thickness). EGFP-
EPCs derived cord-like structure with no blood flow was similarly quantified as
unperfused blood vessel density.
Vascular permeability measurement
Vascular permeability to albumin was determined by intravital microscopy as described
previously[9]. Briefly, mice were injected with a bolus (100 p•) of 1%
tetramethylrhodamine-labeled bovine serum albumin (Molecular Probes, Eugene, OR) in
saline via the tail vein. Fluorescence intensity of the tissue was measured every two
minutes for a total of 20 min by a photomultiplier (9203B, EMI, Rockaway, NJ) using a
20x objective lens. The effective vascular permeability (P) was calculated as follows: P =
(1-HT) V/S [1/(Io - Ib) * dI/dt + 1/K] where I is the average fluorescence intensity of the
whole image, Io is the value of I immediately after the filling of all vessels by rhodamine-
BSA and Ib is the background fluorescence intensity. HT is the average hematocrit. V and
S are the total volume and surface area of vessels within the tissue volume within the
view field, respectively. The time constant of BSA plasma clearance (K) was 9.1 x 103 s.
Analysis of leukocyte-endothelial interaction
Leukocyte-endothelial interaction in the engineered vessels was determined as described
previously[8]. Briefly, endogenous leukocytes were labeled with an intravenous bolus
injection of 50 ld of 0.02% rhodamine-6G and then visualized with intravital microscopy.
For each animal, 3 to 4 blood vessels were randomly chosen that resembled post-capillary
venule based on width of diameter (20 to 40 [tm) and blood flow pattern. Video images
were recorded and 60 seconds of the recordings were analyzed offline. The number of
rolling leukocytes and total flux of leukocytes was counted along a 100 [tm segment of
vessel. Rolling leukocytes were defined as cells interacting with and moving along the
vessel wall at a velocity that was significantly lower than the centerline velocity. The
ratio of rolling cells to total flux (rolling count) was used as an indicator of leukocyte
rolling. Leukocyte rolling was determined at the baseline and after stimulation with
IL 1P (R&D Systems, Minneapolis, MN)[10, 11]. For induction of systemic
inflammation, mice were injected intraperitoneally with 100 ng of IL-1 3 for 4 hours.
Red blood cell velocity analysis
Red blood cell (RBC) velocities along the central axis of 15-25 [tm diameter vessels in
both host and engineered vasculature networks were measured using the line scan
modality of the MPLSM to image RBC[8, 12]. Mean RBC velocity was determined from
the mean orientation angle of the RBC motion using a custom image segmentation
program written in Matlab (Mathworks, Natick, MA).
Statistical analysis
All data were analyzed by ANOVA with the Fisher post hoc test. All data are reported as
mean with standard error. Statistical significance was set at P< 0.05.
Results and Discussion
To obtain EPC-derived colonies, we cultured PB and CB mononuclear blood cells on
Type I collagen-coated dish for 14 to 21 days[6]. We confirmed the endothelial
phenotype of PB- and CB-derived EPCs by immunocytochemistry and flow cytometry.
EPCs from both sources expressed multiple endothelial markers, including CD31, VE-
Cadherin, vWF, VEGFR2 and Tie2, incorporated acetylated low-density lipoprotein
(AcLDL), and were negative for the pan hematopoietic marker CD45 and the monocyte
marker CD14 (Figure 3.1).
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Figure 3.1. Expression of endothelial markers in endothelial progenitor cells.
Peripheral blood derived endothelial cells (a) and cord blood derived endothelial cells (b)
expressed endothelial markers including CD31, VE-cadherin, von Willebrand Factor
(vWF) and Tie2, as determined by immunohistochemistry (CD31, VE-cadherin, vWF,
and Tie2, yellow; DAPI, blue). PB-EPCs (c) and CB-EPCs (d) were positive for Dil-
AcLDL uptake. Scale bars, 50 ýtm. (e) After ex vivo expansion of CB-EPCs, over 99% of
the EPCs that are used for in vivo implantation are CD31+CD45- endothelial cells. These
cells are positive for the endothelial-selective markers VEGFR2 and Tie2 and negative
for the monocyte-specific marker CD14 and progenitor/stem cell marker CD 133.
To determine if adult PB- and CB-derived EPCs are able to self-assemble into functional
blood vessels, we implanted EGFP-labeled EPCs alone or co-implanted them with
10T1/2 cells in a collagen/fibronectin gel onto the pial surface in cranial windows[7].
10T1/2 cells, a line of mouse embryonic fibroblasts, have previously been demonstrated
to stabilize endothelial cells by functioning as perivascular-like cells and releasing
paracrine factors[7, 13, 14]. Here, we found that both human adult PB- and CB-EPCs
were capable of vasculogenesis. However, the density and persistence of the engineered
neovasculature were substantially different depending on the source of EPCs.
In the case of PB-EPCs co-implanted with 10 T 1/2, the EPCs began to elongate and to
connect to one another resulting in a mesh-like network 7 days after implantation (Fig.
3.2a). By day 11, some of the EPCs had joined together to form patent vascular tubes that
were connected to the host circulation (Fig. 3.2a). However, the number of these
functional engineered vessels was low and they were distributed haphazardly within the
collagen gel. Co-implantation of PB-EPCs with 10T1/2 cells did not significantly
increase both perfused and non-perfused vessel densities compared to PB-EPC
implantation alone (Fig. 3.2b and Fig. 3.3a). This is in contrast with in vitro data where
10T1/2 cells promote cord-like formation by the EPCs. With time, the PB-EPC derived
blood vessels began to regress and disappeared almost completely 1 month after
implantation, regardless of the absence or presence of 10 T1/2 cells (Fig. 3.2b and Fig.
3.3a). Occasionally, a few of the blood vessels remained 27 days after implantation (Fig.
3.2c).
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Figure 3.2. Vasculogenic potential of peripheral blood (PB)- versus cord blood
(CB)-derived endothelial progenitor cells (EPCs).
PB-EPCs and CB-EPCs were mixed with 1OT 1/2 cells in a collagen gel, and implanted
into cranial windows in SCID mice. Images were taken at periodic time points with
multi-photon laser scanning microscope for in vivo dynamics of vascularization by the
implanted endothelial cells. PB-EPCs formed vascular-like structure 4 days after
implantation and some of them became perfused at day 11. The PB-EPCs derived blood
vessels were transient and almost completely disappeared by day 21 (a). There was no
significant difference in the mean (±SEM) density of functional vessels derived from PB-
EPCs between groups implanted with PB-EPCs only and PB-EPCs with 10T1/2 cells (b)
(n=4 for each group and experiments were performed with three different batches of adult
peripheral blood). In some animals, there were still some sparse but functional blood
vessels 27 days after implantation (c). In contrast, CB-EPCs formed a uniformly dense
network of functional blood vessels (d). Implantation of CB-EPCs alone led to a rapid
regression of the implanted cells while co-implantation of CB-EPCs and 1OT1/2 cells
resulted in a stable and functional vasculature (e) (n=4 for each group and experiments
were performed with three different batches of human umbilical cord blood). The CB-
EPC derived vascular network was stable and functional for more than 119 days in vivo
(f). Green, PB or CB derived endothelial cell expressing enhanced green fluorescent
protein (EGFP); red, functional blood vessels contrast-enhanced by rhodamine-dextran.
Scale bars, 50 ýtm, a, d; 100 ýtm, c, f.
In contrast, CB-EPCs were able to produce a dense network of blood vessels that were
distributed uniformly throughout the collagen gel (Fig. 3.2d). We quantified the vascular
density of the same region of collagen gel over time. In the group with CB-EPCs
implanted alone, the density of engineered blood vessels was low and they quickly
regressed before they could become perfused (Fig. 3.2e and Fig. 3.3b). However, we
found that in the group co-implanted with 10T1/2 cells, CB-EPCs formed a network of
microvessels that remained stable and patent for more than 119 days (Fig. 3.2e and Fig.
3.3f). We observed some host vessels infiltration into the gel, however the majority of the
blood vessels were CB-EPC derived. The collagen gel was excised and whole-mount
staining with human specific antibodies showed the expression of the endothelial
markers, CD31 and VE-cadherin, on the EGFP-positive EPC-derived vascular
endothelial cells (Fig. 3.4a,b). Collagen Type IV staining revealed that the engineered
blood vessels had an intact basement membrane (Fig. 3.4c). The 10T1/2 cells persisted
and functioned as perivascular cells in vivo (Fig. 3.5a,b).
We next investigated whether implanting CB-EPCs at a higher density could obviate the
need for 10T1/2 pericyte precursors. CB-EPCs were implanted alone at a 5-fold increase
in cell density (5 million cells/ml versus 1 million cells/ml). Some of the implanted CB-
EPCs aligned into functional blood vessels, however these vessels were only transiently
perfused and disappeared by 23 days (Fig. 3.5c). Implantation of 10T1/2 cells alone led
to a minimal angiogenic response. These findings re-affirm that co-implantation of
endothelial and perivascular cells is critical for vasculogenic vessel remodeling and
sustenance.
a b
< 140
E
u 120
E S100
> 80
c 60
4O
40
S20
S0
IOU1
S140 -
E 120-
E 100-
Z 80-
S60-
S40*
• 20-
. u
SCB-EPC with 10T1/2
OCB-EPC alone
) U ,
0 20 40 60 80
day in vivo 0 20 40 60 80day in vivo
Figure 3.3. Engineered vessel density of PB-EPC and CB-EPC.
PB-EPCs or CB-EPCs were mixed with 10T1/2 cells in a fibronectin/collagen gel, and
implanted into cranial windows in SCID mice. Images were taken at periodic time points
with multi-photon laser scanning microscope for in vivo dynamics of vascularization by
the implanted endothelial cells. The vessel density of unperfused blood vessels was
quantified. There was a gradual reduction in the density of unperfused vessels in both
groups of animals implanted with PB-EPCs only and PB-EPCs with 10T1/2 cells (a).
There was no significant difference between the two groups. In the group implanted with
CB-EPC only, there was a rapid decrease in the density of unperfused vessels (b). In the
group co-implanted with CB-EPCs and 10T1/2 cells, there was a gradual decrease in the
density of unperfused vessels and some of the unperfused vessels persisted even at late
time points.
Figure 3.4. Immunohistochemistry of CB-EPCs derived blood vessels.
Whole mount staining of the implanted collagen gel revealed that the CB-EPCs (EGFP+)
at day 87 after implantation maintained the expression of CD31 (a) and Ve-Cadherin (b)
and had intact basement membrane of Collagen Type IV (c) in vivo (EGFP, green; CD31
and Collagen Type IV, red).
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Figure 3.5. Immunostaining of smooth muscle markers in CB-EPCs derived vessels.
Whole mount staining of collagen gel with CB-EPCs (EGFP+) and 10T1/2 cells
(DsRed+) at day 33 after implantation. 10T1/2 cells proliferated and became part of the
stroma in vivo. Some of the 10T1/2 cells functioned as perivascular cells around blood
vessels. Only the perivascular portion of 10T1/2 cells expressed smooth muscle markers,
SM22a (a) and Desmin (b) in vivo (EGFP, green; DsRed, red, SM22a and Desmin,
blue). CB-EPCs implanted alone at high cell density (5 million cells/ml at high density
vs. 1 million cells/ml at normal density) were not able to form long-lasting blood vessels
(c).
The long-lasting functional blood vessels might be linked to a higher proliferative
capacity of CB-EPCs. Indeed, Ingram et al. showed that CB-EPCs have a higher level of
telomerase activity when compared to PB-EPCs[6]. We found a significantly higher
percentage of CB-EPCs were positive for the Ki-67 proliferation marker as compared to
PB-EPCs (65.9% for CB-EPCs versus 38.3% for PB-EPCs, p<0.01) (Fig. 3.6a,b,e),
confirming a proliferative advantage for CB-EPCs.
In addition, PB-EPCs might have a competitive disadvantage compared to CB-EPCs due
to poorer survival[ 15]. Cell transplantation is often inefficient. For example, it has been
estimated that less than 1% of implanted cells survived 4 days after implantation into a
mouse heart[16]. We tested in vitro the EPCs' resistance to stress-induced apoptosis by
exposing them to serum-free medium for 48 hour. After 48 hours of exposure to serum-
free media, only 3.7% of CB-EPCs were apoptotic (i.e., positive for terminal
deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL)) versus 13.3% of
the PB-EPCs (Fig. 3.6 c,d,f). These findings suggest that CB-EPCs are more resistant to
stress-induced apoptosis, in addition to having a proliferative advantage when compared
to PB-EPCs.
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Figure 3.6. Comparison of proliferation and apoptosis in PB-EPCs and CB-EPCs.
Peripheral blood (a) and cord blood (b) derived endothelial cells were stained for Ki-67, a
marker for proliferating cells (Ki-67, yellow; DAPI, blue). PB (c) and CB (d) derived
endothelial cells were exposed to serum free media for 48 hours and the cells were then
stained for TUNEL, a marker for apoptotic cells (TUNEL, red; DAPI, blue).. Quantification
of Ki-67 positive cells showed that a higher percentage of CB-EPCs was undergoing
proliferation (e). Quantification of TUNEL positive cells showed that CB-EPCs exhibited a
higher resistance to serum free medium-induced apoptosis (f). Scale bars, 100 rim, a, b
Scale bars, 50 pm, c, d; *P<0.01, #P<0.001
Finally, the function of the engineered blood vessels is critical, since functional
abnormalities can have serious pathological consequences[17]. For example, two major
problems with immature blood vessels are the irregular flow and the increase in
permeability. This leads to leakiness of plasma proteins or even hemorrhage, similar to
blood vessels inside tumors[ 18]. We measured the permeability to serum albumin of the
CB-EPC-derived blood vessels at 2 months after implantation. We found that CB-EPC-
derived vessels have low vascular permeability, with values close to those of the
neighboring brain capillaries (Fig. 2e). We have not detected any hemorrhagic episode
during the period of observation. The average blood flow rate was comparable between
the CB-EPC derived vessels and host pial vessels (Fig. 2f and Supplement Fig. 9).
Besides serving as a conduit for blood, vascular endothelium should also have the ability
to become activated to recruit leukocytes in the setting of homeostasis, infection or tissue
injury. To test this in CB-EPC-derived endothelium, we induced systemic inflammation
by injection of ILlp in mice with CB-EPC-engineered vessels[10]. We measured the
number of rolling leukocytes at baseline and 4 hours after injection of IL 1 3 in selected
engineered blood vessels that had characteristics of post-capillary venules (based on
morphology, diameter, and rate of blood flow). In these engineered vessels, we found a
significant increase in the percentage of rolling leukocytes after induction of systemic
inflammation suggesting that CB-EPC derived endothelium undergoes proper cytokine
activation (Fig. 2g).
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In summary, we found that CB-EPCs have enhanced vasculogenic ability in vivo
compared to adult PB-EPCs. Moreover, CB-EPC co-implantation with pericyte
precursors led to the formation of long-lasting and functionally normal blood vessels,
providing an attractive cellular therapy platform for tissue engineering.
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Chapter 4: Use Of Human Mesenchymal Stem Cells
Portions of the chapter have been taken from:
P. Au, J. Tam, D. Fukumura, R.K. Jain, Bone marrow derived mesenchymal stem cells
facilitate engineering of long-lasting functional vasculature. Blood (In Press)
Abstract
Vascular tissue engineering requires a ready source of endothelial cells and perivascular
cells. Here, we evaluated human bone marrow-derived mesenchymal stem cells (hMSCs)
for use as vascular progenitor cells in tissue engineering and regenerative medicine.
hMSCs expressed a panel of smooth muscle markers in vitro including the
cardiac/smooth muscle specific transcription co-activator, myocardin. Cell-cell contact
between endothelial cells and hMSCs up-regulated the transcription of myocardin.
hMSCs efficiently stabilized nascent blood vessels in vivo by functioning as perivascular
precursor cells. The engineered blood vessels derived from human umbilical cord vein
endothelial cells and hMSCs remained stable and functional for more than 130 days in
vivo. On the other hand, we could not detect differentiation of hMSCs to endothelial cell
in vitro and hMSCs by themselves could not form conduit for blood flow in vivo. Similar
to normal perivascular cells, hMSCs-derived perivascular cells contracted in response to
endothelin-1 in vivo. In conclusion, hMSCs are perivascular cell precursors and may
serve as an attractive source of cells for use in vascular tissue engineering and for the
study of perivascular cell differentiation.
Introduction
Human bone marrow derived mesenchymal stem cells (hMSCs) are intensively
investigated for treating patients with ischemic heart disease and post-myocardial
infarction. It has been hypothesized that MSCs, when injected into a failing heart, can
differentiate into mature cardiomyocytes or secrete soluble factors that promote
angiogenesis and enhance cardiomyocyte survival and functions[l]. Based on promising
results from preclinical animal models, a number of clinical trials have been initiated to
test the clinical efficacy of hMSCs injection. The early results of the clinical trial have
been mixed and the exact mechanism of the cardiac improvement remains unresolved[2].
In order to maximize the therapeutic potential of hMSCs, a detailed analysis of the
cellular functions of the injected hMSCs is needed.
Data from animal studies have suggested that some of the injected hMSCs can
differentiate into endothelial cells or smooth muscle cells. Some of the MSCs were found
to express endothelial markers including CD31 and vWF, while others expressed smooth
muscle markers including a-smooth muscle actin and desmin[3, 4]. These data suggest
that hMSCs may function as vascular progenitors. These results raise several fundamental
questions. First, can hMSCs differentiate into endothelial cells and smooth muscle cells
in vitro? Second, if MSCs differentiate into endothelial cells and/or smooth muscle cells,
can these cells be used to form functional blood vessels in vivo? Third, do the MSCs-
derived blood vessels respond appropriately to physiological stimulation? These are
important outstanding questions that need to be addressed in order to maximize the
therapeutic potential of MSCs. To address these questions, we utilized a tissue engineered
blood vessel model[5-7] and monitored the cellular fate of implanted MSCs and their
vasculogenic potential by intravital microscopy.
Materials and Methods
Cell culture
Human bone marrow-derived mesenchymal stem cells were purchased from Cambrex
and maintained in Mesenchymal Stem Cell Growth Medium (Cambrex, East Rutherford,
NJ). MSCs were seeded at a density of 6000 cell/cm 2 and the cells were passaged at 90%
confluent. All experiments with wild type hMSCs and EGFP-hMSCs were performed
below 8 and 16 cell passages, respectively. Human umbilical cord vein endothelial cells
(HUVECs) were obtained from Center of Excellence in Vascular Biology, Brigham and
Women's Hospital and maintained in Endothelial Growth Medium (Cambrex). MS1, a
mouse pancreatic endothelial cell line was obtained from ATCC (Rockville, MD).
Human aortic vascular smooth muscle cells (CRL-1999) and human dermal fibroblasts
(CRL-2575) were obtained from ATCC. 293ET packaging cells were a kind gift from
Dr. Brian Seed (Massachusetts General Hospital, Boston, MA). All cells were maintained
at 370 C in a humidified 5% CO2 incubator.
Retrovirus Packaging and Transduction
The retrovirus vector for transducing enhanced green fluorescent protein (EGFP),
PBMN-I-EGFP was kindly provided by Dr. Gary Nolan (Stanford, CA). For retrovirus
packaging, the plasmids of PBMN-I-EGFP, Gag-pol and VSVG (15 tg, 7 [tg, 5 [Lg
respectively) were mixed and co-transfected into 293ET cells with lipofectamine 2000
(Invitrogen, Carlsbad, CA) per manufacturer's protocol. After overnight incubation, the
293ET cells were washed with PBS and replaced with fresh media. The next day, the
supernatant containing retrovirus was collected and fresh media was added; this step was
repeated 3 more times. After the supernatant was collected, it was passaged through a
0.45 I.m filter (Whatman, Middlesex, UK) and was either used immediately for infection
or kept at -800 C.
Co-Culture of Mouse Endothelial Cells and Human Mesenchymal Stem Cells
hMSCs were cultured either alone or co-cultured with MS 1 endothelial cells in
Dulbecco's Modified Eagle's Medium (DMEM) with 2% fetal bovine serum (FBS) for 2
days. Briefly, 1x10 5 hMSCs in the hMSCs only group or 1X10 5 hMSCs and 1X10 5 MS1
endothelial cells in the co-culture group were added to a 6-well plate. The plate was
agitated to make sure the cells were well mixed and the plate was then placed in a 370C
incubator and cultured for 48 hours. For transwell culture, 1X10 5 hMSCs were placed in
a 6 well plate and 1X10 5 MS1 endothelial cells were added onto a 0.4 [tm pore membrane
insert (Coming, Coming, NY) that was placed above the 6 well plate.
Reverse Transcription (RT)-Polymerase Chain Reaction (PCR) and Quantitative Real-
time RT-PCR
Total RNA was extracted with the Qiagen RNeasy mini kit, and cDNA was synthesized
from RNA using TaqMan Reverse Transcription Reagents (Applied Biosystems,
University Park, IL); all procedures were performed according to manufacturer's
protocol. PCR for detection of endothelial and smooth muscle transcripts was performed
with 2.5x Mastermix (Eppendorf, Hamburg, Germany). Quantitative RT-PCRs were
performed on the Applied Biosystems 7300 Real-Time PCR System (Applied
Biosystems). All experiments were performed in triplicate. Final quantification of each
cDNA sample was relative to human GAPDH following the manufacturer's instructions
(Applied Biosystems). Species-specific primers were designed using Primer Express or
Primer3 (Whitehead Institute, Cambridge, MA).
PCR primer sequence and PCR condition
Name Forward primers Reverse Primers Annealing PCR
Temperature cycle
a-smooth ctgttccagccatccttcat cggcttcatcgtattcctgt 520C 30
muscle
actin
SM22a aacagcctgtaccctgatgg atgacatgctttccctcctg 520C 30
Calponin tccaaatatgacccccagaa cccactctcaaacaggtcgt 520C 30
Smoothelin ggagaactggctgcactctc gaaacctctgcctgctgttc 520C 30
ACLP cgcctacggagaaagtcaag cacaaaatcgtcatggatgc 52 0C 30
Desmin tgaagggcactaacgattcc ctcagaacccctttgctcag 520C 35
Myocardin ctcggcttcctttgaacaag cttcccagagaatccatcca 520C 35
VE- aagcctctgattggcacagt acacactttgggctggtagg 520C 30
Cadherin
PECAM1 gagtcctgctgacccttctg cactccttccaccaacacct 520C 30
GAPDH catgagaagtatgacaacagcct agtccttccacgataccaaagt 520C 25
Transwell Migration Assay
Cell migration was assessed using Falcon HTS FluroBlok 24-well inserts (BD
Biosciences, San Jose, CA) with 8-ptm pores. EGFP-hMSC cells (2 x 104) suspended in
250-tpl DMEM (Invitrogen) with 2% FBS were placed inside each insert while 5 x 104
per well HUVECs suspended in 800 tpl EGM (Cambrex) were plated on a 24-well plate.
Eight hours later, all cell culture media were changed to DMEM with 2% FBS, and then
the inserts were placed in the respective wells. To examine the effect of PDGFR
inhibition on cell migration, 2, 5 or 10 tiM of Gleevec (Novartis, Basel, Switzerland) was
added to the medium. The number of migrated cells was quantified 24 hours later as
previously described[8]. Briefly, the image was threshold and the area covered by the
migrated cells was quantified in ImageJ (version 1.38, http://rsb.info.nih.gov/ij/).
Mesenchymal Stem Cell Differentiation Assay
Mesenchymal stem cells were cultured in chamber slides with adipogenic or osteogenic
differentiating medium. Adipogenic medium consisted of DMEM, 10% FBS, 0.5 mM
isobutylmethylxanthine, 10 [tM insulin, 200 [tM indomethacin, and 1%
peniciilin/streptamycin. Osteogenic medium consisted of DMEM, 10% FBS, 0.1 [M
dexamethasone, 50 [M ascorbate-2-phosphate, 10 mM b-glycerophosphate and 1 %
penicillin/streptamycin. After 30 to 40 days in culture, the cells were stained with Oil Red
O and Alizarin Red or alkaline phosphatase for adipogenesis and osteogenesis,
respectively.
Immunofluorescence
Mesenchymal stem cells were grown on chamber slides until confluent. The cells were
washed with phosphate buffered saline (PBS) and then fixed by incubating them in ice-
cold methanol for 30 minutes. The chamber slides were then washed with PBS to remove
all traces of methanol. To block non-specific binding, the chamber slides were incubate
in PBS with 3% bovine serum albumin (BSA) for 1 hour followed by overnight
incubation with primary antibodies at 40C. The following primary antibodies were used
at 1:200 dilution: a-smooth muscle actin (Dako, Glostrup, Denmark), sm22a (Abcam,
Cambridge, MA), desmin (Dako), and NG2 (Chemicon, Temecula, CA). The next day,
the chamberslides were washed with PBS and incubated with appropriate Cy3-conjugated
secondary antibodies (Jackson ImmunoResearch, West Grove, PA). The chamber slides
were then washed and mounted in Vectashield containing DAPI (Vector Laboratories,
Burlingame, CA). For whole mount staining, collagen gels were extracted from cranial
windows and incubated in 4% paraformaldehyde for 3 hours and then washed with PBS.
The gels were initially blocked for endogenous mouse IgG with Vector Mouse on Mouse
Kit (Vector Laboratories) for two hours following manufacturer's protocol. The gels were
then incubated overnight at 40C in blocking solution containing 3% BSA, 5% normal
rabbit serum, and 0.3% Triton X100 in PBS. The next day, primary antibodies (a smooth
muscle actin (Dako), Sm22a (Abcams), and Desmin (Dako)) were diluted in blocking
solution at a dilution of 1:400 and were added to the gel. After overnight incubation with
primary antibodies at 40C, the gels were washed extensively with PBS to remove
unbound antibodies. The gels were then incubated with Cy5-conjugated secondary
antibodies at 1:400 dilution for 3 hours at room temperature. After washing with PBS, the
gels were mounted in Vectashield and imaged with a confocal microscope
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(Model#BX61WI, Olympus, Tokyo, Japan) using 20X/0.95 NA water objective. Image
was acquired with Fluoview FV500 (Olympus).
Tissue Engineered Blood Vessel Model
The engineered blood vessel model was prepared as previously described[5]. Briefly, 1 x
106 HUVECs and 2 x 105 hMSCs cells, or 1 x 106 HUVECs and 2 x 105 10T1/2 cells, or
1 x 106 HUVECs alone were suspended in 1 ml oftype 1 collagen-fibronectin solution.
The next day, a skin puncher (4-mm diameter) was used to create a circular piece from
the collagen gel. The circular piece of collagen gel was then implanted into a cranial
window of a severe combined immunodeficient (SCID) mouse. The in vivo fate of the
fluorescent protein-labeled endothelial cells and hMSCs was tracked by intravital
imaging with multi-photon laser scanning microscopy at various time points[9] (modified
Axioskop 50 microscope, Carl Zeiss, Germany and MaiTai Ti:Sapphire laser, Spectra-
Physics, Mountain View, CA). Image was taken with 20x/0.50 NA water objective.
Functional blood vessels were revealed by intravenous injection of 100 ld of
tetramethylrhodamine-conjugated dextran (2,000,000 MW at 10mg/ml) via the tail-vein.
The same regions in each gel were tracked at different time points for consistency. The
perfused vessel length density was quantified by manual tracing of perfused blood vessels
lined by EGFP-EPCs with a custom-written MATLAB macro (Mathworks, Natick, MA).
Arteriolar Contractility Assay
Arteriolar contractility was assessed by vasoactive response to endothelin-l (ET-1). After
careful removal of the cover glass, the cranial window was superfused with warm PBS.
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For vessel contrast enhancement, 100 jil of 1% tetramethylrhodamine -dextran (MW 2
million) was injected i.v. The engineered vessels were monitored by multi-photon laser
scanning microscopy with a 20x water-immersion objective. After baseline
measurements of vessel diameter, the cranial window was superfused with 100 nM ET-1
in PBS. Then, the same region of vessels was imaged every 5 minutes over a 20 minutes
period. The diameter of vessels was quantified manually with ImageJ.
Statistical analysis
All data were analyzed by ANOVA with the Fisher post hoc test. All data are reported as
a mean with standard error. Statistical significance was set at P< 0.05.
Results
Transcriptional profile for endothelial and smooth muscle markers
To investigate whether hMSCs exhibit endothelial phenotypes, we first checked by PCR
for transcripts of endothelial markers, PECAM1 (CD31) and VE-Cadherin. These
endothelial-selective markers were not detectable in hMSCs, neither at baseline nor when
co-cultured with a mouse endothelial cell line (Figure 4. la). Next, we assessed the
transcription profile of a panel of smooth muscle markers in hMSCs and compared it to
aortic smooth muscle cells and dermal fibroblasts (Figure 4.lb). All cell lines commonly
transcribed mRNA of a-smooth muscle actin, sm22a, desmin, calponin, and smoothelin.
Immunochemistry confirmed the expression of a-smooth muscle actin, SM22a, desmin
and NG2 in hMSCs (Figure 4.1 c-f). Myocardin was recently discovered to be a
cardiac/smooth muscle specific co-activator for serum response factor in the regulation of
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a number of cardiac and smooth muscle genes[ 10]. As expected, myocardin was
transcribed in aortic smooth muscle cells. More interestingly, myocardin was transcribed
by mesenchymal stem cells, but not by dermal fibroblasts. These data suggest that the
expression of myocardin might potentially be a more specific marker for smooth muscle
cell differentiation than the commonly used markers, such as, ca-smooth muscle actin and
SM22a.
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Figure 4.1. Transcriptional profile of endothelial and smooth muscle markers in
hMSCs
a, RT-PCR analysis of endothelial markers (VE-Cadherin and PECAMI) in hMSCs at
baseline and in hMSCs co-cultured for 3 days with MS 1 mouse endothelial cell line. b, RT-
PCR analysis of smooth muscle markers' mRNA in human mesenchymal stem cells, human
aortic vascular smooth muscle cells (CRL-1999) and human dermal fibroblasts (CRL-
2575). Water was used as negative control. c-f, Protein expression of smooth muscle
markers in hMSCs was confirmed by immunohistochemistry (a-smooth muscle actin (c),
SM22a (d), desmin (e) and NG2 (f), yellow; DAPI, blue). Scale bar, 50 tm.
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Endothelial cells up-regulate myocardin in hMSCs through cell-cell contact
Previous studies have suggested that endothelial cells can induce the differentiation of
smooth muscle cells/pericytes[ 11, 12]. To determine whether endothelial cells could
regulate the differentiation of hMSCs toward smooth muscle lineage, we co-cultured
them with a mouse endothelial cell line, MS 1. Using human specific primers, real-time
RT-PCR was performed to examine the transcription of myocardin in hMSCs. Co-
culturing hMSC with MS 1 resulted in a statistically significant up-regulation of
myocardin (Figure 4.2a). TGFP1 has been suggested to be involved in the differentiation
of smooth muscle cells/pericytes[ 11]. We investigated whether addition of TGFP1 could
induce transcription of myocardin in hMSCs. TGF1l stimulation only modestly induced
the transcription of myocardin and the magnitude of the induction was much less
compared to the co-culture group (Figure 4.2a). To gain better understanding of the
inductive signals, we checked whether the signals were mediated by soluble factors or
cell-cell contact. To this end, we cultured hMSCs and endothelial cells in separate layers
of a transwell culture. This allowed for the diffusion of soluble factors while preventing
direct cell-cell contact between hMSCs and endothelial cells. The transwell culture did
not induce myocardin transcription, suggesting that the inductive signal was provided by
cell-cell contact (Figure 4.2a).
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Figure 4.2. Induction of myocardin transcription and migration in hMSCs by endothelial cells
a, Quantitative real time PCR was performed to assess the induction of myocardin in hMSCs by various
conditions after 2 days (hMSCs alone, hMSCs cultured with MS 1 endothelial cells with contact, hMSC
cultured with MS1 without contact by transwell culture, and hMSCs stimulated with TGF 31 (10ng/ml)).
Values expressed as fold increase above hMSC alone levels and normalized by GAPDH. Representative
data of 3 separate experiments. b, Transwell migration assay was performed to assess endothelial cells
induced hMSCs migration. Gleevec at 0.2 [tM, 2 [M, and 10 [iM was added to test for inhibition of
hMSCs migration. # p<0.0001 (medium vs. HUVEC), * p<0.0005 (2 tM Gleevec vs. HUVEC),
**p<0.0001 (10 [tM Gleevec vs. HUVEC).
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hMSCs migrate toward endothelial cells in response to PDGF
A necessary step in the process of vessel maturation is the recruitment of perivascular
cells to stabilize an immature vessel. Therefore, we investigated whether HUVECs could
induce hMSCs migration in a transwell migration assay. In comparison to control
(medium alone), HUVECs significantly increased the number of hMSCs that migrated
across the transwell membrane (Figure 4.2b). Previous data suggested that PDGFR
signaling mediated the process of perivascular cell migration and recruitment[ 11, 13]. To
test whether PDGFR signaling is involved in hMSCs migration, we added Gleevec, a
potent inhibitor of PDGFR, to the cell culture medium. Gleevec blocked hMSCs
migration and PDGF-Rp3 phosphorylation in a dose-dependent manner (Figure 4.2c).
Mesenchymal stem cells functionally stabilize engineered blood vessels
Endothelial cells implanted in vivo could form functional vessels, but such vessels
quickly regressed unless the endothelial cells were ectopically transduced to express bcl2,
an anti-apoptotic gene[ 14]. We previously demonstrated that co-implantation of
endothelial cells with 10 T 1/2, a murine embryonic fibroblast cell line which differentiates
into perivascular cells in vivo, could lead to the formation of a stable and functional
microvascular network without the need for genetic modification of the endothelial
cells[5]. We investigated whether hMSCs could functionally replace 10T1/2 to stabilize
engineered blood vessels. EGFP labeled HUVECs were implanted alone or co-implanted
with hMSCs or 10T1/2 cells in a collagen/fibronectin matrix in a mouse cranial window.
The implanted endothelial cells were observed with multi-photon laser scanning
microscopy to assess their ability to form functional blood vessels. When EGFP labeled
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HUVECs were implanted alone, some vessels formed but they quickly regressed, similar
to previous observations made by us and others (Figure 4.3a and 4.4a,c)[5, 14]. When
EGFP labeled HUVECs were co-implanted with hMSCs, the endothelial cells assembled
into functional blood vessels that anastomosed to the host vascular network (Figure 4.3b
and 4.4a,c). The engineered blood vessel densities derived from HUVEC-hMSC and
HUVEC-1OT1/2 co-implantations were similar (Figure 4.3b-c and 4.4b,d). Furthermore,
the HUVEC-hMSC engineered vessels were stable and remained functional for more
than 130 day in vivo (Figure 4.4e).
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Figure 4.3. hMSCs stabilized engineered blood vessels in vivo
EGFP labeled HUVECs were either implanted alone (a) or co-implanted with hMSCs (b)
or 10T1/2 cells (c) in a collagen gel onto cranial windows in SCID mice. Images were
taken at periodic time points with multi-photon laser scanning microscope to monitor the
in vivo dynamics of vascularization by the implanted endothelial cells. Green, HUVECs
expressing EGFP; red, functional blood vessels contrast-enhanced by rhodamine-dextran.
Scale bar, 50 ýtm.
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Figure 4.4. Quantification of functional engineered blood vessel density.
Quantification of functional and non-functional engineered vessels density in SCID mice
implanted with HUVECs alone and HUVECs with hMSCs (a,c) and HUVECs with
hMSCs or 10T1/2 (b,d) (results are mean±SEM, n=3 in (a,c) and n=5 in (b,d), different
batches of HUVECs were used in study (a,c) and (b,d) resulting in variation in vessel
density between the two experiments). e, The hMSCs stabilized vascular network
remained functional for more than 130 days in vivo. Scale bar, 100 [lm.
Mesenchymal stem cells differentiate into perivascular cells in vivo and respond to
endothelin-1 stimulation
To examine the spatial orientation of hMSCs in relation to the engineered vessels,
hMSCs and HUVECs were transduced with retrovirus to express EGFP and DsRed-
Express (DsRed), respectively. Retroviral transduction of EGFP did not affect the
multipotent nature of hMSCs as assessed by their ability to differentiate into adipocytes
and osteocytes (Figure 4.5). We then investigated whether EGFP-hMSCs implanted alone
could self-assemble into functional vessels. We were not able to detect lumen formation
or blood flow in EGFP-hMSCs derived cells if implanted alone even after 25 days in vivo
(Figure 4.6a). In contrast, in mice co-implanted with DsRed-HUVECs and EGFP-
hMSCs, EGFP-hMSCs were observed to elongate into thin slit structures and coalesced
around the HUVECs derived vessels (Figure 4.6b-f). The number of interstitial EGFP-
hMSCs decreased with time and most of them were associated with blood vessels by day
83 in vivo (Figure 4.6g). These EGFP-hMSCs-derived cells behaved like perivascular
cells with a single layer of cells wrapping around the endothelial tube. Furthermore,
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EGFP-hMSC-derived pericyte-like cells were positively stained for a-smooth muscle
actin, sm22a and desmin (Figure 4.7a-h).
ECTFP Alkaline Phosphatase Merye
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Figure 4.5. In vitro differentiation assay for EGFP labeled hMSCs.
EGFP transduced hMSCs were cultured in adipogenic or osteogenic medium for 30-40
days. a,b, Micrographs of undifferentiated hMSCs (a, EGFP; b, brightfield). c, Oil Red O
staining after adipogenic culture. d, Alizarin red staining after osteogenic culture. e,
EGFP-hMSCs were stained with alkaline phosphatase for osteogenic differentiation.
Scale bar, 100 [m.
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Figure 4.6. Intravital monitoring of EGFP-hMSCs in a tissue-engineered vessel
model.
Fibronectin-collagen constructs with EGFP-hMSCs alone (a) or EGFP-hMSCs with
DsRed-HUVECs (b-g) were implanted into cranial windows of SCID mice. Images were
taken at different time points with MPLSM (b, day 7; c,d, day 19; e,f, day 31; g, day 83).
Green, human mesenchymal stem cells expressing EGFP (a-g); red, HUVECs expressing
DsRed-express fluorescent protein (b-e,g); red, functional blood vessels contrast-
enhanced by rhodamine-dextran (d,f). Scale bar, a,b,g 100 [tm; c,d,e,f, 50 ýim
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Figure 4.7. Expression of smooth muscle cell markers in hMSC-derived cells
incorporated into the tissue-engineered vessels.
Whole mount staining was performed for the extracted tissue-engineered vessel
constructs. a-h, confocal microscopy images for DAPI staining, blue (a); DsRed-
HUVEC, red (b);EGFP-hMSCs, green (c,f,i); a-smooth muscle actin staining, blue (d);
SM22c staining, blue (g); and desmin staining, blue (j). Region of co-localized staining
of EGFP and smooth muscle markers_are highlighted as white (e,h,k). a-e, f-h, i-j are the
same location/construct. Scale bar, 100 ýtm
Pericytes have been shown to possess contractile abilities that directly regulate the blood
brain barrier and local tissue perfusion[ 15]. To determine the function of the EGFP-
hMSCs derived perivascular cells, we stimulated the blood vessels with endothelin-1, a
potent contractile agent. The EGFP-hMSCs covered blood vessels constricted upon
endothelin-l stimulation (Figure 4.8a). The blood vessels narrowed within five minutes
exposure to endothelin-l and remained constricted at 20 minutes (Figure 4.8a-b). These
experiments support the notion that EGFP-hMSCs have the capacity to differentiate into
perivascular cells that can properly respond to physiological stimulation.
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Discussion
Cellular therapy with hMSCs has great potential for use in regenerative medicine and is
currently in clinical development. MSCs are being investigated in treatment of bone and
cartilage defects, and injured myocardium after acute infarction [16]. The ability of
MSCs to differentiate into several lineages of connective tissue including osteocyte,
chrondrocyte, and adipocyte, is well documented[17]. Recent evidence has suggested that
MSCs may also differentiate into endothelial and vascular smooth muscle cells[18]. In
this report, we set out to clarify the cellular fate of implanted mesenchymal stem cells in
participating in vasculogenesis in vivo. Our study showed that hMSCs did not
spontaneously differentiate into endothelial tubes that were capable of carrying blood
flow in vivo. On the other hand, hMSCs differentiated into and functioned as perivascular
cells in vivo when co-implanted with endothelial cells. The hMSCs-derived perivascular
cells were able to stabilize nascent blood vessels, and the engineered blood vessels
remained functional for more than 130 days in vivo. Furthermore, the hMSC-derived
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Figure 4.8. Endothelin-1 stimulated vasoconstriction of the engineered blood vessels.
HUVEC/hMSC-derived engineered blood vessels were superfused with 100nM of
endothelin-1 to stimulate vasoconstriction in vivo. a, representative multiphoton
microscopy images during endothelin-1 superfusion. Green, EGFP-hMSCs; red,
functional blood vessels contrast-enhanced by rhodamine-dextran. Scale bars, 50 [im. b,
The blood vessel diameter was quantified over a 20 minutes period (n=4). The value was
expressed as a fraction of the original diameter. Scale bar, 50 iim
perivascular cells exhibited proper physiological function by constricting in response to
stimulation by endothelin-1, an endogenous vasoconstrictive peptide.
It has long been known that endothelial cells and hematopoietic cells shared a common
origin during development, but whether a common progenitor exists for endothelial cells
and smooth muscle cells has been unclear[19]. The first hint of the existence of vascular
progenitor cells came from an in vitro differentiation study with mouse embryonic stem
(ES) cells[20]. Flkl positive cells were generated and they were shown to have the
potential to differentiate into either endothelial cells or smooth muscle cells depending on
the growth factors in the culture medium. More recent evidence suggested such ES
derived cells might even be capable of differentiating into cardiomyocytes[21, 22].
Besides the work with ES cells, other data also hinted at the close link between
endothelial cells and smooth muscle cells. Under certain in vitro culturing conditions,
endothelial cells and smooth muscle cells could take on one another's phenotypic
markers, but it remains unclear whether this was due to an artifact of in vitro culture or a
process of transdifferentiation[23]. Similarly, hMSCs have been induced to acquire
endothelial and smooth muscle phenotype in vitro[l 8]. An unresolved question is
whether the hMSCs-derived endothelial cells and smooth muscle cells can function
properly with the acquired phenotype in vivo.
To systematically address these outstanding questions, we first began by evaluating the in
vitro transcription of endothelial and smooth muscle markers. We were not able to detect
endothelial markers in hMSCs at baseline and when cultured with a mouse endothelial
cell line. The lack of endothelial marker expression suggested hMSCs had not
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differentiated into endothelial cells with the chosen culturing condition. We could not
discount the possibility that we had not identified the optimal differentiation protocol for
endothelial cells. However, one difference between our study and previous studies was
that we used PCR to detect endothelial markers, a more sensitive and selective method
compared to the immunofluorescence based methods that were used in other studies [18].
We found that hMSCs expressed a number of smooth muscle markers. When co-cultured
with endothelial cells, the cardiac and smooth muscle specific transcription co-activator
myocardin was up-regulated more than 14 fold. The induction of myocardin was
dependent on direct heterotypic cell-cell contact. Since TGF-P has been shown to be
involved in smooth muscle differentiation and the activation of latent TGFP requires
cellular contact, we stimulated hMSCs with recombinant TGF-P1[11, 24]. The magnitude
of myocardin induction induced by the given dose(s) of TGF-31 is only a small fraction
of the myocardin upregulation by endothelial cells. Interestingly, the extent of myocardin
induction by TGF-l1 in hMSCs was similar to the results obtained with multipotent adult
progenitor cells[25]. These data suggest other cell-contact mediators might be involved in
smooth muscle cell differentiation[26].
Our data suggest hMSCs efficiently differentiate into perivascular cells when co-
implanted with endothelial cells in tissue-engineered vessel model in vivo. The hMSC-
engineered vessels may be an ideal model to study perivascular cell differentiation. While
we had previously shown that 10T1/2 cells could function as perivascular cells in
stabilizing engineered blood vessels, there are obvious drawbacks in using 10T1/2 cells
in study of vessel maturation. 10T1/2 cells were shown to lack the expression of the
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transcription co-activator myocardin even when stimulated by TGF31[27]. It was
speculated that TGF P stimulation of 10T1/2 cells might represent a myofibroblast
response instead of true differentiation into vascular smooth muscle lineage[28]. In
contrast, hMSCs expressed a number of smooth muscle markers including myocardin.
These cells could be easily manipulated in vitro, and unlike smooth muscle cells
extracted from discarded tissue, hMSCs are in a relative primitive state of differentiation.
Compared to embryonic stem cells, hMSCs do not carry the potential risks of teratoma
formation and difficulty in obtaining a pure population of lineage specific cells. hMSCs
could potentially be genetically engineered for studying the vascular effects of embryonic
lethal genes.
A previous study has investigated tissue-engineering bone by co-implantation of
endothelial and hMSCs[29]. It was thought that secretion of BMP4 from endothelial cells
stimulated the differentiation of hMSCs into osteocytes. In our study, we were not able
to detect bone or cartilage formation in vivo. Most of the surviving hMSCs were
associated with blood vessels, suggesting that heterotypic interaction between hMSC and
endothelial cells provided a survival advantage for both endothelial cells and hMSC-
derived perivascular cells. One potential reason for the lack of bone or cartilage
differentiation is that EGFP transduction affected the multipotential of hMSCs. The
EGFP-labeled hMSCs were able to differentiate into both osteocytes and adipocytes in
vitro, but it is unclear how EGFP transduction might affect cell differentiation in vivo.
Another reason for the lack of bone formation could be attributed to the mechanical
property of the tissue-engineered construct. Depending on the stiffness of the matrix,
hMSCs could spontaneously differentiate into different cell lineages[30]. In our study, we
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used a matrix (Type I collagen/fibronectin) at a concentration with low stiffness and this
might have prevented osteocyte differentiation. This finding is especially important in the
setting of revascularization therapy with hMSCs since ectopic bone formation has
potentially untoward effects.
In conclusion, we demonstrated that hMSCs specifically differentiated into perivascular
cells that could stabilize nascent blood vessels and responded appropriately to vasoactive
stimuli. hMSCs provide as an attractive cellular platform for vascular engineering and for
studying perivascular cell differentiation.
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Chapter 5: Genetically Engineered Endothelial Cells to
overexpress PDGF-BB
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Abstract
Therapeutic revascularization induced by exogenous angiogenic growth factors or
endothelial cells has yet to demonstrate efficacy in the clinic. Injection of angiogenic
growth factors often produces unstable and abnormal blood vessels, and implantation of
vascular endothelial cells results in unstable vascular network due to a lack of
perivascular cells. Here, we tested a combination of growth factor and cellular
approaches. To enhance recruitment of perivascular cells, human umbilical vein
endothelial cells were genetically modified to overexpress PDGF-BB. PDGF-BB-
overexpressing endothelial cells promoted the proliferation and migration of perivascular
cells in vitro. When the endothelial cells were implanted alone in vivo, endothelial cells
that only expressed EGFP formed transient blood vessel network that regressed
completely by day 30. In contrast, PDGF-BB overexpression enhanced the survival of
endothelial cells in vivo, however the vessel network failed to anastamose to the host
circulation. Co-implantation of PDGF-BB overexpressing endothelial cells with smooth
muscle precursor cells unexpectedly resulted in the rapid regression of the endothelial
cells in vivo. These results suggest angiogenic growth factors, endothelial cells and
smooth muscle cells could interact negatively and their use in combination should be
tested in vivo for unforeseen effects.
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Introduction
Angiogenesis, the growth of new blood vessels, is critical during tissue repair and
regeneration[l]. In cases of insufficient or impaired angiogenesis, the injured tissue
remains dysfunctional and may suffer from irreversible damage[1l]. To this end, two
broad approaches have been employed for enhancing angiogenesis: (i) delivery of pro-
angiogenic genes (by gene transfer) or proteins (by bolus injection or controlled release
devices) for endothelial and perivascular cell recruitment[2], and (ii) delivery of
endothelial cells alone or together with perivascular cells[3].
Therapeutic angiogenesis requires temporally and spatially orchestrated delivery of
required growth factors to achieve a functional and durable vasculature. A number of
studies have shown that a single angiogenic factor may not be able to create a mature and
stable vasculature. For example, injection of an adenoviral vector expressing VEGF into
normal tissue leads to highly disorganized, leaky and hemorrhagic vessels[4].
Furthermore, VEGF can potentiate inflammation by increasing the expression of
adhesion molecules or the release of chemokines[5-8]. The angiogenic vessels are also
highly unstable and regress upon removal of the angiogenic stimuli. Vascular maturation
and stabilization requires perivascular cells[2, 9]. Perivascular cells such as vascular
smooth muscle cells and pericytes are thought to provide structural integrity to the blood
vessels, lay down the extracellular matrix, and provide necessary survival factors to the
endothelial cells[2].
One potential way to enhace vessel maturation is by sequentially delivering VEGF and
PDGF-BB[10]. Such strategy was shown to induce mature vascular networks, but the
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time required for host endothelial cell infiltration by this strategy might limit the amount
of ischemic tissue rescued. Another limitation with angiogenic therapy is that vascular
response to angiogenic factors is reduced with age, hyperglycemia and
atherosclerosis[ 11]. Finally, patients with diabetes mellitus or elevated homocysteine
may exhibit impaired angiogenic response[12, 13].
Alternatively, vascular cells can be directly injected or implanted in the ischemic site.
We have previously shown that human umbilical cord vein endothelial cells (HUVECs)
implanted in a collagen gel in severe combined immunodeficient (SCID) mice could form
functional engineered vessels, but the vessels were only transiently perfused, did not
recruit adequate number of perivascular cells from the host tissue, and regressed within a
few weeks. In contrast, co-implanting HUVECs with mouse pericyte precursor cells
allowed the formation of stable and functional engineered vessels[14]. Thus, providing
exogenous perivascular cells overcame the inability of the implanted endothelial cells to
recruit host perivascular cells within a critical timeframe for the vessels to become
mature and stabilized. Nevertheless, translation of this approach will require sources of
both endothelial and perivascular cells in sufficient numbers for cell-based therapy of
ischemic tissues. So far, such sources remain elusive, despite promising but inconclusive
results obtained with bone marrow-derived precursor cells or embryonic stem cells[15,
16].
To this end, here we tested a combination of these two approaches. We engineered
endothelial cells to overexpress PDGF-BB, a mitogen and a chemoattractant for
perivascular cells. We hypothesized that by increasing the levels of PDGF-BB expressed
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by endothelial cells, it may be possible to hasten the recruitment of perivascular cells
from the host in an appropriate timeframe to stabilize the nascent blood vessels.
Material and Method
Cell culture
Human umbilical cord vein endothelial cells were obtained from Center of Excellence in
Vascular Biology, Brigham and Women's Hospital, Boston and maintained in
Endothelial Growth Medium (EGM) (Cambrex, East Rutherford, NJ). 293ET packaging
cells were a kind gift from Dr. Brian Seed (MGH, Boston). 10T1/2 cells were purchased
from American Type Culture Collection (ATCC, Manassas, VA). All cells were
maintained at 370C in a humidified 5% CO2 incubator.
Retrovirus Plasmid Construction
The retrovirus vector, PBMN-I-EGFP was kindly provided by Dr. Gary Nolan (Stanford,
CA). Human PDGF-B cDNA was purchased from InvivoGen (San Diego, CA). Full
length PDGF-B cDNA was subcloned into the retroviral vector by first using PCR to add
BamHI and NotI restriction sites with the following set of primers: forward primer-
GAATTCGGATCCATGAATCGCTGCTGGGCG and reverse primer-
AAGCTTGCGGCCGCCTAGGCTCCGAGGGTCTC. The PCR product was cut with
BamHI and NotI restriction enzymes and then inserted into the multicloning sites of
PBMN-I-EGFP vector.
Retrovirus Packaging and Transduction
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For retrovirus packaging, the plasmids of PBMN-I-EGFP, Gag-pol and VSVG (15 g,
7 [tg, 5 [tg respectively) were mixed and co-transfected into 293ET cells with
lipofectamine 2000 (Invitrogen, Carlsbad, CA) per manufacturer's protocol. After
overnight incubation, the 293ET cells were washed with PBS and then given DMEM
10%FBS. The next day, the supernatant containing retrovirus was collected and fresh
media was added; this step was repeated for 3 more times. After the supernatant was
collected, it was passaged through a 0.45 [tm filter (Whatman, Brentford, UK) and was
either used immediately for infection or kept at -800 C. For the transduction of HUVECs,
the supernatant was first diluted 1:1 with fresh EGM and supplemented with polybrene
(8[ig/ml). The diluted supernatant was then added to subconfluent monolayer of
HUVECs and allowed to incubate for 4 hours. Fresh EGM medium was exchanged at the
end of the incubation period and this step was repeated 2-3 times on consecutive days.
After 2 to 3 rounds of infection, more than 90% of HUVECs expressed the gene of
interest as assessed by the expression of EGFP. HUVECs expressing EGFP only or co-
expressing PDGF-BB and EGFP will be referred to as HUVEC-EGFP and HUVEC-
PDGF-BB hereafter.
Western Blot for PDGF-R and VEGFR-2 phosphorylation
For PDGF-R phosphorylation, 10T1/2 cells were starved overnight in 0.5% FBS. The
cells were then exposed to conditioned media from HUVEC-PDGF-BB for 5 minutes to
stimulate the phosphorylation of PDGF receptor. The cells were washed three times with
PBS containing ImM NaVO4 and 50mM NaF and then were lysed with RIPA buffer
containing protease inhibitor and phosphatase inhibitor. Immunoprecipitation was
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performed by the addition of 5 ml of anti-PDGFRbeta antibodies (#3162) (Cell Signaling,
Danvers, MA) to cell lysates containing 0.5mg of total protein and was incubated
overnight at 40 C. The next day, the antigen-antibody conjugate was precipitated with
Agarose A/G. Phosphorylated PDGFR-beta was immunoblotted with an anti-
phosphotyrosine antibody conjugated with HRP (clone 4G 10) (Upstate, Charlottesville,
VA) and total PDGFR-beta was immunoblotted with an anti-PDGFR-beta antibody
(#3162) (Cell Signaling). For VEGFR-2 phosphorylation, EGFP-HUVEC and PDGFBB-
HUVEC cells were incubated in serum-free medium 1 hr and then incubated with or
without 50ng/ml VEGF for 2-5 min. Then the cells were scraped from plates, pelleted,
and resuspended in lysis buffer. 60 ptg of protein per sample was separated on a 4-15%
acrylamide gradient gel (Bio-Rad). The expression of phopho-VEGFR2, VEGFR2, and
Actin were detected by polyclonal antibodies against VEGF receptor 2 (1:1000) and
phosphorylated VEGF receptor 2 (1:2000) (Cell Signaling), and by monoclonal
antibodies against Actin (1:5000) (Sigma).
Cell proliferation assay
The activity of the ectopically expressed PDGF in HUVEC was assayed by testing its
ability to induce the proliferation of 10T1/2 cells. Briefly, confluent monolayer of
HUVECs that had been transduced with PDGF-BB or EGFP were incubated for 12 hours
with DMEM containing 1% FBS. The conditioned medium was filtered with a 0.22mm
filter and stored in -80TC until ready for use. 10T1/2 cells were plated in a 96 well plate
at a density of 5,000 cells/well. The next day, the medium in each well was removed and
replaced with 100ml of HUVECs conditioned medium and allowed to incubate for 24 hr.
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After 24 hours, 20 ml of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (20mg/ml, Sigma-Aldrich, St. Louis, MO) was added to each well and the plate
was incubated further for 2 hours. The medium was then removed and replaced with
100ml of dimethyl sulfoxide (DMSO). The absorbance was read with a colorimetric plate
reader at 550-655mm wavelength.
Protein measurements by enzyme-linked immuno-sorbent assay (ELISA)
Secreted and cell retained PDGF-BB in HUVECs were quantified with ELISA kit (R&D
Systems). For measuring secreted PDGF-BB, supernatant were collected and filtered
through a 0.22itm filter before measurement. For cell retained PDGF-BB, HUVECs were
first washed with PBS, and then incubated with 1M solution of NaCl for 30 minutes on
ice. The salt solution disrupts the charge-charge interaction between PDGF-BB and the
extracellular matrix. The salt solution was then filtered with a 0.22[tm filter before
measurement.
Transwell migration assay
Cell migration was assessed using Falcon HTS FluoroBlok 24-well inserts (BD
Biosciences, San Jose, CA)with 3-rim pores. EGFP-10T1/2 cells (2 x 104) suspended in
250-gl BME (Invitrogen) with 0.5% FBS were placed inside each insert and 5 x 104 per
well HUVECs suspended in 800 gl EGM (Cambrex) were plated on a 24-well plate. The
cells were kept overnight. The next day, the cell culture media of both HUVECs and
10T1/2 cells were changed to BME with 0.5% FBS, and then the inserts were placed in
the respective wells. At 4, 8, and 12 hours interval, the bottom of each insert was imaged
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in fluorescence using an inverted fluorescence microscope (Olympus IX70, Center
Valley, PA) equipped with a motorized stage and motorized filter wheel (Improvision
Inc, Lexington, MA). For endothelial cells migration, EGFP- and PDGFBB-HUVEC
cells were cultured in Eagle's MEM with 1% FBS for overnight. Cells (6 x 104) were
plated in each insert coated with fibronectin. The filter was placed over a bottom chamber
containing 5ng/ml VEGF (purchased from R & D systems, Minneapolis, MN and
Collaborative Biomedical Products, Bedford, MA) in 0.1% bovine serum albumin (BSA)
in Eagle's MEM medium. The assembled chemotaxis chamber was incubated for 3 h at
370 C with 5% CO 2 to allow cells to migrate through the fibronectin-coated polycarbonate
filter. Transmigrated cells were quantified using ImageJ (http://rsb.info.nih.gov/ij/) by
using threshold function and measuring the area covered by the migrated cells.
Tissue engineered blood vessel constructs
One million endothelial cells and 2x10 5 10T1/2 cells were suspended in 1 ml solution of
rat-tail type 1 collagen (1.5 mg/ml) (BD Biosciences) and human plasma fibronectin (90
[tg/ml) (Sigma) in 25 mM Hepes (Sigma) buffered EGM medium at 40C. The pH was
adjusted to 7.4 by using IN NaOH (Fisher Science, NJ). The cell suspension was pipetted
into 12-well plates and warmed to 370C for 30 minutes to allow polymerization of
collagen. Each solidified gel construct was covered by one ml of warmed EGM medium.
After one day culture in 5% CO2, a skin puncher was applied to create circular disk-shape
pieces of the construct (4-mm diameter), and they were implanted into the cranial
windows in severe combined immunodeficient (SCID) mice[14, 17]. Multiphoton laser-
scanning microscopy was used to visualize and quantify the morphological changes in
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EGFP-expressing HUVECs. The perfused vessels were highlighted by tail vein injection
of 1% tetramethylrhodamine-labeled dextran (MW 2,000,000), indicating the formation
of functional engineered vessels[14, 17].
Cord formation assay was performed identically as above except that the tissue
engineered construct was allowed to culture in vitro. Images of the tissue-engineered
construct were taken randomly at 3, 7, and 12 days with an inverted fluorescence
microscope. The formation of vessel-like network was quantified by thresholding the
image and measuring the area of vessel-like structures with ImageJ.
TdT-mediated dUTP Nick End Labeling (TUNEL) Assay of HUVEC
In situ TUNEL staining (ApopTag peroxidase In situ detection kit, Chemicon, Temecula,
CA) was used according to manufacturer's instructions to identify apoptotic cells. EGFP-
HUVEC and PDGFBB-HUVEC cells were cultured in serum-free medium, in complete
medium, or under hypoxia condition (1% 02-5% CO2-balance N2 was used).
In vitro tube formation assay
In vitro tube formation was studied using previously described procedures*. Matrigel
(Collaborative Biomedical Products, Bedford, MA) was diluted with EC medium in 1:1
ratio. Next, 60 tl of the solution were added to each well of a 96-well plate and allowed
to form a gel at 370C for 30 min. EGFP-HUVEC and PDGFBB-HUVEC (20,000 cells)
cells in 200 tl of complete medium were subsequently added to each well and incubated
for overnight at 370C in 5% CO2. Under these conditions, both EGFP- and PDGFBB-
HUVEC cells form delicate networks of tubes and were fully developed after 16 h.
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Results
Efficient retroviral transduction ofHUVECs
HUVECs were transduced with the retrovirus to express either PDGF-BB or enhanced
green fluorescent protein (EGFP) alone. We utilized a bicistronic retroviral vector that
allows for the expression of both the gene of interest and EGFP. This provides a simple
method to monitor the transduction efficiency of retrovirus by quantifying the percentage
of EGFP expressing cells. After two to three rounds of retrovirus transduction, close to
100% of HUVECs expressed EGFP (Fig. 5.1a,b). Next, we quantified the secretion of
ectopically expressed PDGF-BB with ELISA. In HUVECs overexpressing the PDGF-BB
gene, the amount of secreted PDGF-BB protein in the culture media was significantly
higher than the control that had been transduced to express EGFP only (223.2 ± 1.1
versus 7.6 ± 2.2 Rg of PDGF-BB) (Fig. 5.1c). To examine cell-associated PDGF-BB,
HUVECs were washed with salt solution to disrupt the charge-charge interaction between
PDGF-BB and the extracellular matrix. The amounts of cell-associated PDGF-BB were
98.2 ± 11.3 [Lg and 6.9 + 0.2 [tg for HUVEC-PDGF-BB and HUVEC-EGFP, respectively
(Fig. 5.1d). In the case of HUVEC overexpressing PDGF-BB, a higher ratio of soluble to
cell associated PDGF-BB was observed, possibly due to saturation of binding sites on the
cell surface (Fig 5.1 e).
137
EGFP PDGF-BB
138
C
C
aL
01
g
a
250
200
150
100
50
0
e
,a.
2.52
ors
10.
= 0 .SC70!f o·s
0E
do.
a
4,
I
E
-
EGFP PDGF-88
250-
200
IS-
150
100
50"I
so-0·r
EGFP PDGF-BB
T
EGFP PDGF-BB
Figure 5.1. Retroviral transduction of HUVECs to overexpress PDGF-BB
HUVECs were transduced with retrovirus either to express EGFP only (a) or to co-express
EGFP and PDGF-BB (b). Fluorescence image of EGFP expressing cells (green) with
corresponding brightfield image demonstrate that almost all of the HUVECs expressed
EGFP. The amount of PDGF-BB secretion in the culture media (c) and bound to cell
surface (d) was quantified by ELISA. Ratio of secreted PDGF-BB in culture media to that
on the cell surface showed more PDGF-BB was release in the media in endothelial cells
overexpressing PDGF-BB (d). Scale bar, 50 [tm * p<0.0005, # p<0.05, ** N.S.
Conditioned medium from PDGF-BB-overexpressing HUVECs enhances proliferation
and migration of 1OT1/2
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To assess the function of the ectopically expressed PDGF-BB, we exposed serum starved
10 T 1/2 cells, a mouse mesenchymal precursor cell line, to HUVEC conditioned media.
We previously showed that 10T1/2 cells could function as perivascular-like cells in
vivo[ 14]. HUVEC-PDGF-BB conditioned medium stimulated significantly more
phosphorylation of the PDGF-R[ and higher proliferation of 10T1/2 cells than the
HUVEC-EGFP conditioned medium (Fig. 5.2a,b). Since PDGF-BB is known to induce
recruitment of perivascular cells, we next examined whether overexpression of PDGF-
BB in HUVECs could promote the migration of 10T1/2 cells in vitro. Using Boyden
chamber migration assay, we found a higher number of 10T1/2 cells migrated across a
transwell in the HUVEC-PDGF-BB group than the controls over a 24 hours period (Fig.
5.2c). These findings demonstrated that ectopically expressed PDGF-BB was
functionally active and that the overexpression of PDGF-BB enhanced the migration of
10T1/2 cells in vitro.
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We next checked whether ectopic expression of PDGF-BB altered the phenotype of
HUVECs. The rate of endothelial cell proliferation showed no difference among
HUVEC-EGFP, HUVEC-PDGF-BB, and HUVEC-EGFP supplemented with
recombinant PDGF-BB (Fig 5.3a). HUVEC-EGFP and HUVEC-PDGF-BB also
responded similarly to VEGF stimulated migration (Fig 5.3b). Finally, PDGF-BB
overexpression in HUVECs did not affect the cells ability to form vessel-like structures
on Matrigel (Fig 5.3c).
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Figure 5.2. In vitro activity of PDGF-BB on perivascular cells proliferation and
migration
HUVEC conditioned media (CM) stimulated the phosphorylation of PDGF-RP in 10T1/2
cells (a). Endothelial growth medium was used as control. Conditioned medium from
HUVECs overexpressing PDGF-BB enhanced the proliferation of 10T1/2 cells as
quantified by MTT assay compared to mock transfected HUVECs (EGFP only) (b).
Transwell migration assay was performed to assess HUVECs induced migration of
10T1/2 cells (c) # p<0.0001, * p<0.005
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PDGF-BB overexpression enhanced HUVECs survival in vivo
To create engineered vessels, we implanted HUVEC-PDGF-BB cells in a
fibronectin/collagen matrix onto cranial windows in SCID mice. For control, we
implanted HUVEC expressing only EGFP. We tracked the functional vasculature inside
the gels by multi-photon laser scanning microscopy and monitored the kinetics of blood
vessel formation. In the group implanted with HUVEC-EGFP cells, the endothelial cells
became elongated and interconnected, forming a mesh-like network on day 3 (Figure
5.4a). Multiple vacuoles were observed to have formed within the endothelial cells. By
day 7, some these vacuoles had coalesced into luminal structure (Fig 5.4). On day 18,
blood flow was seen within the lumen of the endothelium suggesting that the engineered
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Figure 5.3. Effects of ectopic expression of PDGF-BB on HUVECs
Overexpression of PDGF-BB in HUVECs did not affect their rate of proliferation (a),
migration (b), and their propensity to form vessel-like structure on matrigel in vitro. Scale
bar, 50 [tm
blood vessels had formed functional connection to the host circulatory network (Fig 5.4).
Similar to previous result, engineered blood vessels derived from HUVEC only were
unstable and most of the vessels had regressed by day 30 (Fig 5.4).
In contrast, in animals implanted with HUVEC-PDGF, the endothelial cells persisted
even at day 30. Similar to the control group, HUVEC-PDGF-BB formed a mesh-like
network with lumen inside it. However, few of these vascular structures were perfused
(Fig 5.4).
Day 3 Day 7 Day 11 Day 18 Day 30
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Figure 5.4. Effect of PDGF-BB overexpression on engineered blood vessels
HUVECs expressing EGFP only (a) or HUVECs co-expressing EGFP and PDGF-BB (b)
were implanted in a collagen gel in cranial windows in SCID mice. Images were taken at
3, 7, 11, 18 and 30 days after implantation with multi-photon laser scanning microscope
to monitor the in vivo dynamics of vascularization by the implanted endothelial cells (n
5 for each experimental group).
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Co-implantation of l OT1/2 cells promoted the regression of PDGF-BB overexpressing
endothelial cells in vivo
Next, we co-implanted HUVECs with 10T 1/2 cells to determine whether exogenously
supplied smooth muscle/pericyte cells could enhance the formation of functional
engineered blood vessels. In the control group with HUVEC-EGFP and 1OT 1/2 cells,
HUVEC-EGFP formed vessel like network at day 4. By day 8, we were able to observe
blood flow inside the lumens (Fig 5.5a). In marked contrast, we found that co-
implantation of HUVEC-PDGF-BB and 10T1/2 cells led to an accelerated reduction in
the density of HUVECs in vivo compared to the control (Fig 5.5b). Quantification of the
total vessel length density showed a reduction in the number of HUVEC-derived vessels
at day 4, and the density dropped precipitously, thereafter (Fig 5.6a). Unlike implantation
of HUVECs alone, which transiently forms new vessels, we did not detect the formation
of any perfused engineered blood vessels in the group implanted with HUVEC-PDGF-
BB (Fig 5.6b).
Day 4 Day 8 Day 12
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Next, we sought to determine if the in vivo phenotype of could be captured in vitro by co-
culturing HUVEC-PDGF-BB with 10T1/2 cells. HUVEC-PDGF-BB and HUVEC-EGFP
were incorporated with 10T1/2 cells in fibronectin/collagen matrix and cultured in vitro.
After 3 days, we observed the formation of vessel-like structures by the HUVECs similar
to those formed in vivo (Fig 5.6a,b). There was no significant difference in the ability of
HUVEC-PDGF-BB and HUVEC-EGFP to morph into the vessel-like structures. The
vessel-like structures in both groups regressed at similar rate with the progression of time
and by day 12, only a few of these structures remained in the collagen gel (Fig 5.6c).
These data suggest HUVEC-PDGF-BB and HUVEC-EGFP when co-cultured with
10T1/2 cells morphed into vessel-like structures with similar efficiency in vitro. The
inability of co-implanted HUVEC-PDGF-BB and 10 T 1/2 cells to form stable blood
vessels in vivo is likely secondary to altered in vivo microenvironment by the
overexpression of PDGF-BB.
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Figure 5.6. In vitro vessel formation by endothelial cells
HUVECs expressing EGFP only (a) or HUVECs co-expressing EGFP and PDGF-BB (b)
were incorporated in collagen/fibronectin gel. Images were taken with fluorescence
microscope at day 3, 7 and 12. No apparent difference was observed in the ability of
HUVEC-EGFP and HUVEC-PDGF-BB to form vessel-like structure in vitro. The
vessel-like structures were quantified (c) Scale bar, 50 [tm. * N.S.
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We further checked whether there's a difference in the intrinsic property of HUVEC with
or without PDGF-BB overexpression. HUVEC-EGFP and HUVEC-PDGF-BB were
serum-starved overnight for the induction of endothelial cell apoptosis. The two groups
of endothelial cells were shown to have similar percentage of apoptotic cells as measured
by TUNEL (Fig 5.7a). Finally, VEGFR-2 signaling was shown to be intact in HUVEC-
PDGF-BB as assessed by VEGFR-2 phosphorylation (Fig 5.7b).
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Figure 5.7. Effect of ectopic expression of PDGF-BB on HUVECs
HUVECs expressing EGFP only or HUVECs co-expressing EGFP and PDGF-BB were
exposed serum-free media overnight for the induction of apoptosis. The number of
apoptotic cells in each group was quantified by TUNEL staining (a). Western Blot of
VEGFR-2 phosphorylation was performed and 13-actin was used as loading control (b).
Discussion
Therapeutic angiogenesis has great promise in its ability to alleviate tissue ischemia and
to help repair damaged tissue. Presently, a number of clinical trials are testing different
angiogenic agents such as VEGF and bFGF to induce new blood vessels in poorly
perfused tissue with the ultimate aim of improve tissue function[ 11]. In parallel, cell-
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based therapy with bone marrow derived progenitor and/or embryonic stem cells is also
being investigated for regenerative medicine[15, 16]. However, it is unclear whether a
combination of these two approaches might yield a better result due to synergistic effects.
In this report, we tested whether overexpressing PDGF-BB in endothelial cells could
hasten the recruitment of perivascular cells and create a stable and long-lasting network
of blood vessels. Our in vitro results demonstrated that PDGF-BB overexpression in
HUVEC promoted the proliferation and migration of 10T1/2 cells. HUVEC-PDGF-BB
when implanted alone showed an increase in the survival of vessel-like structure,
however such structure rarely became perfused even at day 30. In contrast, co-
implantation of HUVEC-PDGF-BB with 10T1/2 cells led to an accelerated reduction in
the number of endothelial cells in vivo. The implanted endothelial cells did not appear to
form any perfused blood vessels and by day 12, almost all the implanted cells had
disappeared.
PDGF-BB has been previously implicated to be involved in vessel maturation. In vitro
studies suggest that PDGF-BB is involved in the recruitment of perivascular cells[18].
This has been further confirmed by genetic knockout model of the ligand (PDGF-BB) or
the receptor (PDGFR-f3)[19]. These two knockout mice share similar phenotypes in that
both mice are embryonic lethal. The blood vessels in the mice are hemorrhagic and show
a reduction in the number of perivascular cells. When PDGF-BB expression is knocked
out specifically in endothelial cells, it causes abnormality in the blood vessels in the
heart, kidney and brain[20]. This suggests that the secretion of PDGF from endothelial
cells is critical during the development of matured vessels. A recent study has added a
layer of complexity - it was shown that not only is the secretion of PDGF-BB important,
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but a gradient of PDGF-BB concentration is necessary for perivascular cell
recruitment[21, 22]. PDGF-BB contains, at its carboxyl terminal end, a sequence of
positively charged amino acids that is termed the retention sequence. It is believed that
the retention sequence of PDGF-BB interacts with the negatively charged components of
extracellular matrix such as heparan sulfate on the cell surface. Normally, most of the
secreted PDGF-BB is retained at the cell surface, thereby limiting their actions to nearby
cells only. Mice that have been genetically engineered to have PDGF-BB deficient in
retention sequence exhibit marked abnormality in the brain blood vessels due to a
reduction in perivascular cells[21].
Based on these observations, we reasoned that incorporating PDGF-BB directly in the
tissue-engineered construct might disrupt the spatial distribution of PDGF-BB. Disabling
the local chemotatic gradient of PDGF-B has been shown to reduce vascularization[23].
Therefore, we engineered the implanted endothelial cells to overexpress PDGF-BB in
order to establish a local chemotatic gradient of PDGF-BB that is critical for pericyte
recruitment in nascent vessels[24]. Indeed, in vitro results suggested that HUVEC-
derived PDGF-BB increases pericyte precursor cell proliferation and migration. The
unexpected finding of our study was that the in vivo phenotype of HUVEC-PDGF-BB
was dependent on the presence of 10T1/2 cells. In the absence of 10T1/2 cells, HUVEC-
PDGF-BB survived better than HUVEC-EGFP in vivo. However, when co-implanted
with 10T1/2 cells, in vivo overexpression of PDGF-BB in HUVECs led to an accelerated
regression of the nascent blood vessels. The exact mechanism for the reduction in the
number of the endothelial cells is unclear; however, saturation of binding sites by
overexpressed PDGF-BB may disrupt gradient of PEGF-BB at the close proximity of
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endothelial cells (Fig. 1 e). Ratio of endothelial cells and pericyte precursor cells may also
play an important role. 10T1/2 cells may overwhelm endothelial cells due to significant
increase in their proliferation by overexpressed PDGF-BB. In fact, it has been shown that
10T1/2 cells suppress HUVECs number when equal number of HUVECs and 10T1/2
cells are co-cultured[25].
PDGF-BB is a known dedifferentiating agent for smooth muscle cells. Stimulation of
smooth muscle cells with PDGF-BB reduces the expression of smooth muscle markers
including a-smooth muscle actin and SM-MHC[26]. Constitutive expression of PDGF-
BB in HUVECs might have inhibited the differentiation of perivascular cells that is
needed to stabilize the blood vessels. Moreover, PDGF-BB stimulation has been shown
to induce VEGF and TGFi1 in 10T1/2 cells in vitro[27, 28]. VEGF is a pro-survival
factor for endothelial cells by activation of the Akt pathway[29]. On the other hand,
TGFP1 has been shown to inhibit proliferation and promote apoptosis of endothelial cells
in vitro [30]. Interestingly, VEGF was shown to act in concert with TGF31 to induce
endothelial cell apoptosis [31]. It is thus possible that endothelial cells overexpressing
PDGF-BB induced the expression of VEGF and TGFP1 in 10T1/2 cells and these two
growth factors in turn promoted endothelial cell apoptosis in vivo.
In summary, our findings show the complexity of in vivo systems in which well-
characterized cells and growth factors are used in combination for therapeutic
angiogenesis, and demonstrate the need to determine optimal dosage, spatial and
temporal distribution of these cellular and molecular elements in vivo.
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Chapter 6: Conclusion
155
One fundamental barrier in creating functional artificial tissue is the lack of a blood
supply to deliver oxygen, nutrients, and to remove metabolic waste. Numerous strategies
have been attempted to solve this challenge. The two main approaches include: 1. The
release of angiogenic factors by mean of delivery of proteins or DNA plasmids to induce
host blood vessels infiltration, and 2. incorporation of cells that directly differentiated
into blood vessels. Each approach has its own advantages and drawbacks. In this thesis, I
mainly focused on the cellular approach and then extended it by investigating a
combination of angiogenic and cellular approaches.
The inspiration of this thesis stems from an intriguing finding. When Bcl2-transduced
HUVECs were implanted subcutaneously in a SCID mouse, the HUVECs formed
functional conduit that connected to the host circulation as demonstrated by the presence
of red blood cells inside the lumen[ 1]. In that study, Schechner et al. demonstrated that
the expression of Bcl2, a proto-oncogene that inhibits apoptosis, was critical in the
survival and maintenance of the HUVEC derived vessels. When untransduced HUVECs
were implanted in a mouse, the endothelial cells quickly disappeared.
These data suggested to us that it was feasible to engineer functional microvessels in vivo
by implantation of endothelial cells. However, the necessity of ectopic expression of
Bcl2 poses a significant drawback due to the potential risks for transformation. Thus, we
explored an alternative strategy to enhance the survival of the engineered blood vessels
without the need for genetic modification. Based on the knowledge our laboratory has
accumulated over the years with tumor blood vessels, we hypothesized that co-
implantation of endothelial cells with an exogenous source of perivascular cells would
stabilize the engineered blood vessels in vivo.
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Tumor blood vessels are noted for their marked abnormality as a consequence of the
excess amount of pro-angiogenic factors secreted by the tumor cells or the tumor stroma.
This imbalance between the pro-angiogenic and anti-angiogenic signals drives the
morphological and functional abnormality of a tumor blood vessel. Tumor blood vessels
are often tortuous and leaky and the pericytes around a vessel are often absent or loosely
attached to the endothelium. Anti-angiogenic therapy can "normalize" the tumor blood
vasculature and helps to improve the clinical efficacy of radiation and chemotherapeutic
treatment by enhancing the delivery of oxygen and chemotherapeutic [2]. How does this
knowledge of tumor blood vessels help us to create and improve an engineered blood
vessel? One important finding discovered in our laboratory was that anti-angiogenic
treatment with anti-VEGFR2 antibodies prunes away immature blood vessels while
leaving the pericyte-covered blood vessels intact and/or by actively recruiting pericytes to
the immature tumor vessels [3, 4]. Mature blood vessels were defined as those that were
circumscribed by pericytes. This result suggests that pericytes play a critical role in
regulating the survival of endothelial cells in vivo. The presence of pericytes was able to
overcome the anti-vascular effects of VEGF blockade.
With this in mind, we decided to co-implant HUVECs with 10T1/2 cells, a line of mouse
embryonic fibroblasts. Previous studies had suggested 10T1/2 cells might function as
pericyte progenitor cells in supporting the maintenance of vascular-like network in vitro
[5]. Our experimental result confirmed this finding in vivo. We were able to demonstrate
that HUVECs when co-implanted with 10T1/2 cells were able to form long-lasting and
stable blood vessels [6]. Some of the HUVEC derived vessels maintained their integrity
for close to one year.
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However, in order to translate this concept to the clinic, we need to utilize cells that can
be secured and used in clinic. To this end, we systematically replace each individual cell
type with a readily available source of cells. In collaboration with Dr. David Scadden' s
laboratory, we explored the derivation of endothelial cells from human embryonic stem
cells (Chapter 2). We were able to induce the differentiation of human embryonic stem
cells to endothelial lineage and demonstrated that these hESC derived endothelial cells
were fully capable of participating in vasculogenesis and to anastomose with a mouse
vascular network when implanted in vivo. However, there remained significant issues
regarding the differentiation efficiency, culture condition, and line of human embryonic
stem cells.
While our differentiation protocol was able to generate enough endothelial cells for in
vivo testing, it remained wholly inefficient. The percentage of CD3 1+ or CD34+ cells
generated was quite variable ranging from 7% to 30% of total number of cells. Some of
the variability can be attributed to different lots of fetal bovine serum used in the study
and different starting size of embryonic stem cell colonies. In the 2D differentiation
protocol, the hESCs were cultured and differentiated with a feeder layer of murine
embryonic fibroblasts (MEFs). The presence of the MEFs may negatively influence the
differentiation process through the release of paracrine factors. Since different batches of
MEFs were used in the study, this may also have contributed to the variability in the
experiment.
Our experience suggests that a more defined and optimized cell culture and
differentiation protocol is needed to increase reproducibility. How to optimize the
differentiation of endothelial cells from hESC? First, a chemically defined cell culture
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medium should be used for both maintenance and differentiation of human embryonic
stem cells. This will minimize the variability caused by fetal bovine serum and MEFs.
Another interesting possibility is to couple the expression of a reporter gene (e.g., EGFP
or luciferase) to an endothelial promoter (ie. VE-Cadherin or Tie2). Under such a system,
endothelial differentiation will drive the expression of a reporter gene allowing for easy
identification of endothelial cells. When coupled with a high throughput screening
system (e.g., microfluidic culture), the reporter gene will aid in the testing of different
combination of growth factors (e.g., BMP4, VEGF) to induce the differentiation of
endothelial cells. With this strategy it may be possible to systematically define the
optimal differentiation protocol for derivation of endothelial cells from human embryonic
stem cells.
Another problem we experienced with hESC differentiation is the growth of non-
endothelial cells within the population CD34+ cells. After two weeks of culturing, we
began to see colonies of non-endothelial cells with fibroblastic morphology. These cells
quickly outgrew the endothelial fraction and eventually became the dominant cell type.
This raises the possibility of a population of vascular progenitor within the CD34+
population and this is supported by a recent study [7]. Alternatively, the endothelial cells
may undergo a process of endothelial-mesenchymal transition and becomes a population
of fibroblast-like cells [8]. However, per Ochkam's razor, the most likely scenario is cell
impurity during the isolation of the CD34+ cells. Even after 2 rounds of magnetic bead
selection, the purity of CD34+ cells only reached 80 to 95% as determined by FACS
analysis. This problem may be partially overcome by use of a selection marker (i.e.
neomycin or puromycin resistance gene) driven by an endothelial promoter (i.e. a Tie2 or
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VE-Cadherin promoter). This concept has already been validated in mouse embryonic
stem cells to genetically select endothelial cells[9].
In our study, we utilized human embryonic stem cells that were derived from discarded
embryos. Besides the associated ethical concerns, there remains a problem of immuno-
compatibility. An exciting development that bypasses both of these concerns is the recent
demonstration of induced pluripotent stem (iPS) cells derived from human adult
fibroblast cells. Simply infecting adult fibroblasts with retrovirus to ectopically express
three to four genes, the fibroblast cells were converted into a population of embryonic
stem cell-like cells[10, 11]. iPS cells hold tremendous promise for regenerative medicine
since they provide a source of renewable and tailored cells that are completely immuno-
compatible with their recipients. An important next step will be to derive endothelial
cells from iPS cells and to demonstrate their in vivo vasculogenic potential.
Since the successful use of ES or iPS-derived cells will likely to take some time, we
investigated an alternative source of endothelial cells, endothelial progenitor cells that are
already being tested for clinical use (Chapter 3). Endothelial progenitor cells can be
isolated from umbilical cord blood and peripheral blood. However, there was a dearth of
data regarding the in vivo persistence and performance of the endothelial progenitor cell
derived blood vessels. We demonstrated that cord blood EPC derived blood vessels
persisted much longer in vivo than those derived from adult peripheral blood EPCs. This
result is not entirely surprising since accumulating evidence suggests the organismal age
of a cell directly impacts cellular function[ 12].
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The outstanding question arising from this project is the differential in vivo survival of
endothelial progenitor cells. In vitro study suggests that cord blood EPCs were more
resistant to serum starvation induced apoptosis than peripheral blood EPCs.
However, this result did not provide a causal link. We attempted by PCR Array to
identify a difference in the transcription level of apoptosis-related genes. Both sources of
EPCs dramatically up-regulated anti-apoptotic genes (e.g., Bcl2) upon serum starvation.
One difference between PB-EPCs and CB-EPCs is the expression of telomerase.
Interestingly, there is data in literature that link telomerase activity with angiogenesis and
anti-apoptosis in endothelial cells. Therefore, it would be interesting to down-regulate the
expression of telomerase in CB-EPCs with RNA interference and then test for the CB-
EPCs in vivo survival and vasculogenic capacity.
Our experiments with human bone marrow derived mesenchymal stem cells suggest that
hMSCs facilitated the engineering of stable and long-lasting microvasculature by
differentiating into perivascular cells (Chapter 4). One intriguing result from this study
was that there appears to be a crosstalk between the hMSCs and endothelial cells for their
survival in vivo. The majority of the hMSCs that persisted in vivo were associated with
blood vessels. In vitro data further suggested that cell-cell contact mediated the
differentiation of hMSCs. It is unclear to us at this time whether both survival and
differentiation signals were provided by the same molecule. We explored some
candidates that may mediate the cell-cell contact dependent signals. We utilized
neutralizing antibodies against N-Cadherin and alpha4betal integrin, but we were not
able to detect changes to myocardin transcript level in hMSCs by real-time PCR. It's
possible that sub-optimal concentration of antibodies was used in this study. The
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molecular mechanisms for the cell-cell contact dependent hMSC differentiation and
survival awaits further elucidation.
The combination of cell and growth factor based approach offers an exciting new way to
induce the formation of functional blood vessels in vivo. We genetically engineered
endothelial cells to constitutively secrete PDGF-BB in the hope that it would hasten the
recruitment of host perivascular cells (Chapter 5). However, we observed that the
endothelial cells quickly died once they are implanted in vivo. This effect was only
observed in vivo, suggesting PDGF-BB over-expression indirectly induces the regression
of endothelial cells through an unknown mechanism. At this time the molecular
mechanism of endothelial cell death remains unclear to us. However, this work
emphasizes the complex nature of the in vivo microenvironment and its interaction with
the implanted cells. Care must be taken in the combined use of cell and growth factor
based approaches in inducing blood vessel growth, since it is likely that unintended
effects may arise.
This thesis has served as a necessary first step in utilizing clinically relevant sources of
vascular cells to create functional microvasculature in vivo. It systematically defines the
optimal source of endothelial cells and perivascular cells for vascular engineering. It has
exposed the difficulty and limitation in the use of human embryonic stem cell derived
endothelial cells. It further illustrates the unintended effects of genetically engineered
endothelial cells. A major barrier in engineering functional tissue is the lack of a
functional microvasculature. We hope that in some small measure this work provides a
guide to overcome this problem and helps to propel the field of tissue engineering
forward to its eventual clinical application.
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